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Abstract
Elevated plasma lipoprotein(a) (Lp(a)) levels are a causal risk factor for cardiovascular disease
(CVD), but development of specific Lp(a) lowering therapeutics has been hindered by
insufficient understanding of Lp(a) biology. For example, the location of the noncovalent
interaction that precedes the extracellular disulfide linkage between apolipoprotein(a) (apo(a))
and apolipoprotein B-100 (apoB-100) in Lp(a) biosynthesis is unclear. In this study we
modulated known intracellular regulators of apoB-100 production and then assessed apo(a)
secretion from human HepG2 cells expressing 17-kringle (17K) apo(a) isoform variants using
pulse-chase analysis. Treating 17K-expressing HepG2 cells with proprotein convertase
subtilisin-kexin type 9 (PCSK9) significantly increased apo(a) secretion. Treating the same
cell line with Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor,
significantly decreased apo(a) secretion. Overexpression of human sortilin variants (F404Y
and K302E) significantly increased apo(a) secretion relative to wild-type. Our findings suggest
a role for sortilin, PCSK9, and MTP in modulating Lp(a) levels through effects on apo(a)
secretion, possibly through impacting the intracellular bioavailability of apoB-100.
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Lay Summary
Lipoprotein(a) (Lp(a)) is a circulating lipoprotein that contributes to the development of
cardiovascular disease. The structure of lipoprotein(a) consists of a low-density lipoproteinlike core that is covalently attached to apolipoprotein(a). Unfortunately, no pharmacological
therapies designed to specifically lower Lp(a) currently exist, which reflects a lack of
fundamental understanding of the mechanisms regulating Lp(a) production and catabolism. In
this study, we modulated known regulators of apoB-100 secretion and subsequently analyzed
apo(a) secretion to determine if a non-covalent interaction exists between apo(a) and apoB100 in Lp(a) production.
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Chapter 1

1

Introduction
1.1 Cardiovascular Disease: Significance &
Pathogenesis

Cardiovascular disease (CVD) remains the leading cause of death in the developed world
[1]. CVD is a general term used to encompass all diseases of the blood vessels and heart.
The most common CVD, accounting for the highest levels of morbidity and mortality, is
coronary artery disease (CAD) [2]. CAD is a progressive disease caused by atherosclerosis,
which is defined by the presence of fatty plaques in the walls of large-and medium-sized
arteries [2]. Although much research has been undertaken to fully elucidate the
pathogenesis of CAD, the steps involved in the disease process are not yet completely
understood [3]. It is believed that an initial insult to the blood vessel induces structural
changes to the intercellular tight junctions between the single layer of endothelial cells that
line the arteries, resulting in increased vessel permeability [3]. Shear-stress, smoking, and
dyslipidemias are all examples of proatherogenic stimuli that can cause endothelial
dysfunction and trigger the development of CAD. Although each cause of endothelial
dysfunction appears quite distinct, further investigation has shown that they all share the
common ability to activate enzymatic systems and cause reactive oxygen species (ROS)
overproduction [4]. This creates an oxidative stress environment within the endothelial
cells. ROS overproduction incites an inflammatory process by inducing the NF-B
pathway and the expression of NF-B dependent genes [4]. VCAM-1, ICAM-1, Eselectins, and cytokines such as TNF- and IL-1, are all examples of NF-B dependent
genes that are expressed in response to ROS production. The expression of these NF-B
dependent genes alters the phenotype of endothelial cells which subsequently results in an
abnormal flux of LDL-cholesterol (LDL-C) and leukocytes into the vessel’s intima layer
[5]. Movement of inflammatory cells and cholesterol into the intimal layer of the vessel
represent the initial steps in atherosclerosis pathogenesis, and precipitate the formation of
local inflammation and fatty streak development [5].
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Monocytes are one example of a leukocyte which migrates into the vessel wall during times
of increased endothelial permeability. As the monocyte moves from the blood to the vessel
intima, it differentiates into a phagocytic macrophage. These macrophages then begin to
ingest oxidized LDL particles through phagocytosis, coat-pitted endocytosis, pinocytosis,
and scavenger receptors [6]. Over time, these macrophages eventually become foam cells,
and are referred to as such because of their lipid-filled, foam-like appearances. Continued
uptake of oxidized lipids by the foam cells eventually results in lysosomal destabilization,
ROS production, and the release of proinflammatory cytokines such as IL-1 and IL-18
[5].

This ROS production and cytokine release acts in a positive-feedback manner to

further induce endothelial permeability, leading to greater accumulation of leukocytes and
lipoproteins in the vessel wall. As a result, the fatty plaque within the vessel intima
continues to grow in size, which leads to vessel narrowing and disrupted blood supply to
downstream tissues.
Continued LDL-C uptake, as well as local intimal inflammation, causes the mechanisms
regulating foam cell cholesterol homeostasis to become overwhelmed [5]. The end result
of this homeostatic dysregulation is endoplasmic reticulum (ER) stress pathway-mediated
apoptosis and necrosis [7]. Foam cell apoptosis and necrosis leads to increased release of
cytokines, which acts both to further propagate the inflammatory response within the
lesion’s necrotic core, and to induce smooth muscle cell (SMC) migration from the tunica
media to the tunica intima [6]. As SMC’s migrate into the tunica intima, they undergo a
phenotypic switch characterized by proliferation and decreased expression of contractile
markers, and form a fibrous cap around the growing atherosclerotic fatty plaque to stabilize
it [8]. As the fatty plaque continues to grow and develop in coronary arteries over several
decades, it can eventually begin to reduce downstream blood flow to the cardiomyocytes
of the heart, which presents clinically as stable angina [9]. Angina is not considered
immediately life-threatening as the blood supply to the heart muscle is only reduced and
not completely occluded. However, without intervention, the lesion can continue to grow,
and the stability of the fibrous cap can become compromised through matrix
metalloproteinase mediated degradation [10]. Continued necrotic core growth and fibrous
cap instability can eventually result in increased risk of plaque rupture. Upon plaque
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rupture, there is immediate thrombosis formation when plaque contents come into contact
with the flowing blood. If the thrombosis completely occludes the coronary arteries, a
myocardial infarction will ensue, whereby the muscles of the heart become ischemic and
potentially necrotic if oxygen-rich blood cannot be re-supplied to the cardiomyocytes in a
timely manner.

1.2 Lipoprotein(a) and Apolipoprotein(a)
1.2.1

Beyond LDL-cholesterol

The “Lipid Hypothesis” proposes that elevated levels of LDL-C contribute to the
development of atherosclerosis. This hypothesis emerged as a result of early studies
conducted by Nikolai Anitschkow. Anitschkow fed rabbits high cholesterol diets and
observed that the extent of atherosclerosis formation was proportional to the absolute
amount of and length of exposure to plasma cholesterol [11]. The “Lipid Hypothesis” has
resulted in the clinical lowering of LDL-C in primary prevention settings to prevent CVD
onset, and in secondary prevention to reduce recurrent event rates. Decades of evidence
from various clinical trials involving more than 170,000 individuals have shown that the
use of statin therapy to lower LDL-C results in reduced cardiovascular event rates [12].
However, recent randomized clinical trials, such as the Scandinavian Simvastatin Survival
Study, have shown that approximately 20% of patients reaching goal LDL-C levels, still
experience cardiovascular events [13]. These results suggest that the pathogenesis of
atherosclerosis may be more complex than originally believed, and this data has pushed
researchers in the cardiovascular field to uncover the existence of other risk factors which
contribute to heart disease in patients who attain optimal LDL-C levels. The focus has
shifted to relationships between HDL-cholesterol levels, elevated triglycerides, and
comorbidities such as diabetes and inflammation with cardiovascular risk. Interestingly,
the 9612 participant JUPITER trial found that among individuals treated with potent statin
therapy, lipoprotein(a) (Lp(a)) was a significant determinant of residual CV risk [14].

1.2.2

Lp(a) as a Causal Risk Factor for CVD

Lp(a) was first described by Käre Berg in 1963 as a lipoprotein particle that shared many
similarities with LDL. Like LDL, Lp(a) is a lipid-rich particle that contains a cholesteryl

4

ester core, a surface monolayer of phospholipids, and a single associated apolipoprotein B100 (apoB-100) moiety [15]. The covalent attachment of a surface polymorphic
glycoprotein called apolipoprotein(a) (apo(a)) to apoB-100 is the only component that
clearly distinguishes Lp(a) from LDL [16]. Due to its structural similarities with LDL,
many researchers began to hypothesize that Lp(a) might also contribute to CAD. Berg’s
group was able to determine that plasma Lp(a) levels were higher in myocardial infarction
survivors than in control patients [15]. Many other early studies showed an association
between elevated plasma Lp(a) and CAD, but these studies were criticized either because
the findings could not be repeated, or because they were retrospective in design and thus
could not distinguish whether or not Lp(a) was a causative risk factor for CAD [17].
The Physician Health Study published in the early 1990’s concluded that there was no
evidence for Lp(a) levels contributing to risk of future MI [18]. In this study, plasma
samples were taken from 195 participants that subsequently developed angina, and from
195 age and sex-matched controls. Lp(a) plasma levels were measured by a commercially
available nephelometric method, and ultimately the results suggested that Lp(a) levels
should not be used as a screening tool to assess future cardiovascular risk. These findings
decreased enthusiasm for Lp(a) research for more than 15 years. However, when this study
was repeated over a decade later using a highly standardized reference-based ELISA
method, it was found that individuals with Lp(a) levels in the top 80th percentile had a 2fold increased risk for developing CAD [19]. In further support of this observation, several
prospective studies utilizing new technologies and modern genetic approaches have also
identified Lp(a) as an independent and causal risk factor for CAD and have sparked
renewed interest in the field of Lp(a) research. Specifically, Mendelian randomization
studies have allowed us to definitively establish a causal relationship between elevated
plasma Lp(a) levels (over 50 mg/dL) and increased risk (2-fold) for CAD [20]. It has also
been identified that roughly 20% of the global population has Lp(a) levels in excess of
50mg/dL, which represents a significant proportion of individuals at elevated risk for future
cardiovascular events [21]. Although Lp(a) is now known to be an independent and causal
risk factor for CAD, the exact mechanisms of how it contributes to the disease have not yet
been fully elucidated.
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1.2.3

Structure of Lp(a) and Apo(a)

The structure of Lp(a) shares many similarities with LDL in terms of its protein and lipid
composition. Like LDL, the lipid core of Lp(a) is rich in cholesteryl esters and
triglycerides, while the surface consists of a monolayer of phospholipids and some
unesterified free cholesterol (Fig. 1.1) [22]. What makes Lp(a) unique from LDL is that it
has a polymorphic apo(a) glycoprotein covalently attached to the apoB-100 component via
a single disulfide bridge (Fig.1.1) [23]. Lp(a) is found circulating exclusively in the plasma
of humans, Old World monkeys and apes [24, 25]. This is due to the fact that the LPA gene
on chromosome 6q26-27, which encodes apo(a), is found and expressed only in these
species [26]. Sequencing work performed by Eaton and colleagues has revealed that the
LPA gene has likely emerged from a duplication of the plasminogen gene [27]. It appears
that the two genes diverged during primate evolution about 40 million years ago [26].
Plasminogen is an inactive zymogen that can be cleaved by tissue plasminogen activator
(tPA) to the active enzyme plasmin at sites of clot formation. Plasmin is an important player
in the fibrinolytic system as it is responsible for degrading fibrin clots. Plasminogen is
composed of a C-terminal serine protease domain, and, like other components of the
fibrinolytic and coagulation cascades, contains five kringle domains (KI, KII, KIII, KIV,
and KV) [28]. Kringles are so-named because of their tri-looped polypeptide structure,
which has been said to be similar in appearance to a Danish pastry. These tri-looped
polypeptide kringles are stabilized by three invariant internal disulfide bridges [29]. The
PLG and LPA genes share roughly 85% sequence identity in both the untranslated and
coding regions, and so it is no surprise that these two genes give rise to proteins that share
many structural similarities [26]. The C-terminal serine protease domain found in
plasminogen is also present in apo(a) but is functionally inactive in the latter [30]. Apo(a)
also contains kringle domains that are somewhat similar in composition to plasminogen’s,
but due to deletion events, apo(a) lacks the plasminogen KI, KII and KIII domains [31].
Instead, apo(a) consists of 10 different plasminogen-like KIV domains (KIV1-10) and a
single plasminogen-like KV domain (Fig. 1.2). These repeated KIV domains can be
divided into 10 subgroups based on differences in amino acid sequence, and likely arose
as a result of gene expansion and differentiation [31]. Each of the 10 KIV domains are
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found in only one copy, with the exception of KIV2, which can have 3 to over 30 identical
tandem repeats (Fig. 1.2) [32]. Differences in the number of tandem repeats in KIV2 is
attributable to allelic variation in the LPA gene and gives rise to apo(a) size heterogeneity
between individuals [33].
The kringle domains of apo(a) are linked by 24-36 amino acids, which are rich in threonine,
serine, and proline [34]. These linker regions are subjected to extensive O-linked
glycosylation within the Golgi [35]. Each apo(a) KIV domain contains at least one possible
site for addition of N-linked glycans, which appear to be important for proper folding and
secretion of the protein [36]. Apo(a) is also similar to plasminogen in that some of its KIV
domains contains amino acid sequences that coordinate lysine binding. Within each lysine
binding site (LBS), there are cationic residues that interact with the C-terminus of lysine,
and anionic residues that interact with the N-terminus of lysine [37]. The bottom of the
LBS pocket is lined by hydrophobic residues that help stabilize the aliphatic lysine
backbone [37]. Specifically, KIV5-8 of apo(a) have each been identified as weak lysine
binding sites (wLBS), whereas KIV10 has been identified as a strong lysine binding site
(sLBS) [37]. These differences in lysine binding ability are due to differences in the amino
acid composition of each kringle. It is also of note that KIV9 possesses a free cysteine
residue (specifically Cys4057) that has been shown to facilitate the covalent linkage between
apo(a) and apoB-100 [38].
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Figure 1.1: Structural components of Lipoprotein(a). Lipoprotein(a) (Lp(a)) can be
distinguished from LDL by the presence of a covalently bound glycoprotein called
apolipoprotein(a) (apo(a)). Like LDL, Lp(a) has a triglyceride (TG) and cholesteryl ester
(CE) rich core that is surrounded by free cholesterol (FC) and a surface monolayer of
phospholipids (PL). Lp(a) is also similar to LDL in that it contains a single associated
molecule of apolipoprotein B-100 (apoB-100). Apo(a) consists of multiple repeated kringle
IV (KIV) domains, a single kringle V (KV) domain and an inactive protease domain (P).
There are 10 distinct subtypes of KIV (KIV1-10) which can be differentiated based on amino
acid sequence. Each KIV domain is found in only one copy, with the exception of KIV2,
which can be found in variable numbers of tandem repeats. The variable repeats in KIV2
give rise to Lp(a) isoform size heterogeneity. Weak lysine binding sites in KIV7 and KIV8
mediate noncovalent interactions with specific lysine residues (Lys) in apoB-100. A free
cysteine in the C-terminal region of the apoB-100 moiety covalently attaches to a free
cysteine in KIV9 of apo(a) to produce a molecule of Lp(a). Adapted from [39].
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Figure 1.2: Structural similarities between apo(a) and plasminogen. Apo(a) shares
considerable homology with plasminogen. Like plasminogen, apo(a) is composed of
multiple kringle domains. Apo(a) has 10 subtypes of kringle IV (KIV) and each subtype,
with the exception of KIV2, is found in only one copy. KIV2 gives rise to the considerable
size heterogeneity of apo(a) between individuals as it can be found in anywhere from 3 to
over 30 identical tandem repeats (an isoform with 5 repeats is shown above). KIV5-8 have
been identified to contain weak lysine binding sites (white stars), and KIV10 has been
identified to contain a strong lysine binding site (red star). KIV9 contains a free cysteine
residue (Cys4057) which is responsible for forming the covalent bond between apo(a) and
apoB-100. Apo(a) also contains a single KV domain and an inactive serine protease (P).
Apo(a) lacks the tail domain, KI, KII, and KIII found in plasminogen. Adapted from [40].
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1.2.4

Proposed Mechanisms of Lp(a) Pathophysiology

As mentioned in section 1.2.2, recent Mendelian randomization studies have identified
Lp(a) as a causal risk factor for CAD [20]. In fact, Lp(a) is now identified as the single
most prevalent inherited risk factor for CVD [21]. Although genetic studies have identified
Lp(a) as a causal risk factor, the mechanisms by which Lp(a) contributes to the disease
process have not been fully elucidated. The structural similarities of Lp(a) to both
plasminogen and LDL has led to the speculation that Lp(a) can contribute to both
atherogenesis and thrombosis. It has been established that during periods of endothelial
dysfunction, LDL can accumulate and be retained in the subendothelial space [41]. The
process of atherogenesis begins when this retained LDL is oxidized, which subsequently
leads to cytokine release, endothelial cell activation, monocyte recruitment, and the
initiation of a pro-inflammatory response [42]. Because Lp(a) contains an LDL-like
component, it was believed that Lp(a) can contribute to atherogenesis in a similar way and
induce this pro-inflammatory state within the subendothelial space. Indeed, it has been
shown that Lp(a) can readily move into the vessel intima layer, be taken up by resident
macrophages, and induce inflammation [43]. However, it is also believed that the apo(a)
component of Lp(a) makes it a distinct risk factor from LDL. Homology between apo(a)
and plasminogen led many to postulate that Lp(a) may have some impact on thrombosis or
fibrinolysis. Importantly, a fluorescence-based in vitro technique showed that Lp(a) was
able to significantly reduce the conversion of plasminogen to plasmin, thus implicating
Lp(a) as a prothrombotic molecule [30]. Therefore, the aforementioned studies suggest that
the Lp(a) particle may be able to uniquely contribute to the pathogenesis of CVD, both
through a pro-inflammatory / proatherogenic arm, and a prothrombotic arm.

1.2.4.1

The Pro-Inflammatory & Proatherogenic Arm:

One of the major ways Lp(a) is thought to contribute to the pathogenesis of CAD is through
its role as an oxidized phospholipid (oxPL) carrier, particularly because of the well-known
pro-inflammatory and pro-atherogenic properties that oxPLs possess. It was originally
believed that the site of apo(a) oxPL addition was within the KV domain. However,
subsequent studies showed the presence of oxPLs on apo(a) variants that lacked the KV
domain [44]. Leibundgut’s findings, coupled with more recent in vitro work, have
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determined that the apo(a) KIV10 domain is the site of oxPL addition, as disruption of the
lysine binding site within this domain results in the inability of apo(a) to bind to oxPLs
[45]. It has been shown through in vitro and in vivo work that oxPLs preferentially bind
covalently to the apo(a) KIV10 domain of Lp(a) [46]. In fact, transfer studies have shown
that oxidized LDL particles will donate their oxPLs to Lp(a) in a time-and temperaturedependent manner [46]. OxPLs appear to influence atherogenesis by initiating robust
immune responses that attract leukocytes to the site of vascular lesions. Several studies
have demonstrated the ability of oxPLs in apo(a) to activate pro-inflammatory pathways
and stimulate the release of various cytokines [47]. Oxidation of apo(a) has been associated
with increased release of IL-8, a cytokine responsible for leukocyte recruitment [45].
Furthermore, in vitro and in vivo analysis has identified Lp(a) as a leukocyte
chemoattractant through its ability to stimulate the release of monocyte chemoattractant
protein-1 (Mac-1) [48]. Mac-1 is an important player in inflammatory responses by
increasing the migration and infiltration of monocytes to sites of injury [48]. Although the
mechanism by which Lp(a) modulates the release of Mac-1 has not yet been elucidated, it
is plausible to speculate that the oxPLs of apo(a) play some role in this ability to stimulate
chemotaxis.
In terms of changes in vascular endothelium, Lp(a), through its apo(a) KIV 10 strong LBS,
has been shown in vitro to induce a RhoA/Rho-kinase signaling cascade; this, in turn,
results in stress fiber formation, and ultimately causes endothelial cell contraction and
increased vessel permeability [49]. Studies in human umbilical vein endothelial cells
(HUVECs) showed that apo(a) can further increase vascular permeability by causing
disruptions in VE-cadherin/-catenin complexes in a SRC dependent process [49]. Apo(a)
has also been shown to alter vascular endothelium by inducing expression of E-selectin
[50] and ICAM-1 [51], which are important leukocyte adhesion molecules that initiate the
translocation of monocytes from the vessel lumen to the vascular intima.
Apo(a) has also been shown to modulate endothelial cell and SMC migration. Migration
assays showed that apo(a) induced strong RhoA and integrin V3-dependent SMC
chemorepulsion [52]. SMC chemoattraction is a common feature of the pathogenesis of
atherosclerosis as these cells act to increase plaque stability. Therefore, by acting as a SMC
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chemorepellent, it is believed that apo(a) subsequently decreases plaque stability and
increases vulnerability to rupture [52]. Furthermore, the oxPLs on Lp(a) have been shown
to induce apoptosis in endoplasmic-reticulum stressed macrophages. This effect was
mediated through CD36 and TLR2 signaling, and led to plaque necrosis and subsequent
plaque vulnerability [53] (Fig. 1.3).

12

Figure 1.3: The proatherogenic effects of Lp(a) and apo(a) on macrophages and
endothelial cells. The apo(a) KIV10 domain possesses a sLBS site capable of covalently
binding oxPLs. The oxPLs on apo(a) can stimulate macrophages to release the proinflammatory IL-8 chemokine. Apo(a) mediated IL-8 production and release from
macrophages appears to be dependent on TLR binding and NF- signaling. The oxPL
component of apo(a) can also trigger apoptosis in ER-stressed macrophages. The apoptotic
event is dependent on signaling through TLR2 and CD36, and contributes greatly to plaque
necrosis and vulnerability. Apo(a), through its oxPL component, can also induce
cytoskeletal rearrangements through RhoA/Rho-kinase signaling, which subsequently
increases endothelial permeability. Furthermore, apo(a) oxPLs are able to stimulate
endothelial COX2 production through AKT-mediated nuclear translocation of -catenin.
COX2 is believed to play an important role in the formation and maintenance of
atherosclerotic plaques. The endothelial receptors responsible for Lp(a)-mediated
cytoskeletal rearrangements and COX2 expression have not yet been elucidated. Finally,
the oxPL component of apo(a) can induce proliferation and migration of both endothelial
cells and smooth muscle cells through integrin V3 signaling and FAK-mediated MAPK
pathway activation. FAK, Focal adhesion kinase; MLCP; myosin-light-chain phosphatase;
NF-, Nuclear factor-; ROS, Reactive oxygen species; TLR2, toll-like receptor 2.
Adapted from [47].
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1.2.4.2

The Prothrombotic Arm:

As mentioned, apo(a) and plasminogen share extensive sequence homology. This has led
many researchers to postulate a role for Lp(a) as a prothrombotic factor in CVD. This idea
arose specifically because the protease domain of apo(a) retains the ability to bind to lysinecontaining substrates but lacks any enzymatic activity [40]. Apo(a) has not been shown to
have any inhibitory effect on fibrin clot break down in the presence of fully activated
plasmin [54]. However, several in vitro studies have clearly indicated that apo(a) and Lp(a)
are able to inhibit tPA-mediated plasminogen activation and thus subsequently inhibit tPAmediated clot lysis [55, 56]. Furthermore, apo(a) has been shown to reduce the plasminmediated positive feedback loop that results in the conversion of Glu1-plasminogen to
Lys77-plasminogen [57]. Lys77-plasminogen lacks the tail domain, which in turn makes it
a better tPA substrate and enhances plasminogen activation. Therefore, although apo(a)
does not appear to inhibit the activity of active plasmin, it has been shown to attenuate both
tPA-mediated plasminogen activation and the positive-feedback loop of plasmin-mediated
plasminogen activation, thus implicating Lp(a) as an anti-fibrinolytic factor. Sequences
within KIV5-8, the sLBS in KIV10, and the KV domain appear to be essential to the
inhibition of plasminogen activation [58]. The impact of each domain to the inhibition of
plasminogen activation has not yet been identified. However, it can be predicted that the
complex 3-dimensional structure of apo(a) is responsible for making contacts with
plasminogen, fibrin, and potentially tPA, and thus it is possible that this complex protein
structure accounts for the antifibrinolytic properties of Lp(a). In fact, in vitro studies using
a 12-kringle apo(a) isoform have demonstrated that apo(a) can interact with fibrin, tPA and
plasminogen [30].
In vitro and animal model studies have also provided evidence that apo(a) and Lp(a) may
enhance atherothrombotic platelet aggregation. Specifically, one study has indicated that
apo(a) is able to enhance platelet aggregation and granule release mediated through the
thrombin receptor-activating hexapeptide SFLLRN [59]. Lp(a) also appears to contribute
to atherothrombosis through its ability to bind to tissue factor pathway inhibitor (TFPI).
TFPI suppresses coagulation through its ability to bind to Factor Xa and subsequently the
tissue factor/Factor VIIa complex [60]. Therefore, by binding to TFPI Lp(a) is able to
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suppress the anti-coagulant activities of this inhibitor. In summary, in vitro and animal
model studies have provided evidence that the prothrombotic arm of Lp(a) pathogenesis
appears to involve both the attenuation of plasminogen activation, as well as
atherothrombotic platelet aggregation.

1.2.5

Determinants of Plasma Lp(a) Concentrations

Plasma levels of Lp(a) can vary over 1000-times between individuals [61]. Circulating
levels of Lp(a) appear to be largely dictated by production and secretion rather than by
catabolism. Early studies using radiolabeled tracers showed that no relationship existed
between plasma Lp(a) levels and fractional catabolic rate (FCR), but very strong
correlations existed between plasma Lp(a) levels and production rates [62].
As mentioned, the KIV2 domain of apo(a) can be found in anywhere from 3 to over 30
identical tandem repeats and this gives rise to the considerable apo(a) size heterogeneity
between individuals. It is this size heterogeneity, which is dictated by the LPA allele size,
that is the main determinant of plasma Lp(a) concentrations [62]. In vitro studies in baboon
hepatocytes have shown that smaller apo(a) isoforms are secreted more efficiently than
larger ones. This supports the inverse relationship that has been reported in the population
between apo(a) isoform size and plasma Lp(a) concentrations [63]. This is of clinical
interest because it suggests that individuals with smaller apo(a) isoform sizes will have
higher plasma concentrations of Lp(a), which, as mentioned previously, is now recognized
as a causal risk factor for CVD. To support this idea, a large meta-analysis of 58,000
phenotyped subjects revealed that individuals with less than 22 KIV2 repeats had a 2.08fold increased relative risk of CAD than individuals with more than 22 KIV2 repeats [64].
It was originally hypothesized that smaller apo(a) isoform sizes were secreted more
efficiently than larger isoforms due to increased rates of protein folding. It was later shown
that the rate of protein folding in the ER is identical for all apo(a) isoforms [63]. However,
it was determined that the rate of post-translational maturation of apo(a) through
carbohydrate chain addition differs between different apo(a) isoform sizes. Pulse-chase
studies in baboon hepatocytes have revealed that both an immature, hypoglycosylated form
of apo(a), and a mature, fully glycosylated form of apo(a) can be isolated from cell lysates
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[65]. Importantly, only the mature, fully glycosylated form is secreted. Each KIV domain
has one potential site of N-linked glycosylation, whereas the linker regions between KIV
domains have up to 6 potential O-linked glycosylation sites [66]. For this reason, apo(a)
alleles with higher numbers of KIV2 repeats can have upwards of 300 O-linked and 50 Nlinked carbohydrate chains [63]. The aforementioned pulse-chase studies in baboon
hepatocytes also showed that only the immature form of apo(a) was detected in the first 30
minutes of chase. The mature, fully glycosylated form of apo(a) could not be detected until
30-60 minutes of chase time. This suggests that the maturation of apo(a) through
carbohydrate chain additions may be a rate limiting step in Lp(a) production and account
for plasma Lp(a) concentration differences between different apo(a) isoform sizes [65].
Interestingly, another study conducted in baboon hepatocytes showed that the use of
tunicamysin, an inhibitor of N-linked glycosylation, as well as castanospermine, an
inhibitor of N-linked glucose trimming, both completely prevented apo(a) maturation and
secretion [63]. Therefore, it can be concluded that both the addition and the trimming of
these N-linked glucose molecules is essential for apo(a) to move through the secretory
pathway. In summary, it appears that larger apo(a) isoform sizes have increased retention
times in the ER which leads to increased degradation via the ERAD pathway and presents
clinically as decreased levels of plasma Lp(a) [67].
Although this inverse trend does appear to exist in most cases, the relationship between
LPA allele size and Lp(a) levels can still vary quite extensively. In fact, the copy number
variations in KIV2 have been found to only account for about 75% of the variation in Lp(a)
plasma concentrations [68]. Several genetic studies have been able to identify sequence
variations within the LPA gene, that are causally associated with Lp(a) levels. For example,
a rs1853021 single nucleotide polymorphism (SNP) in the 5’-flanking region of the LPA
gene has been shown to introduce an alternative start codon, which leads to 60% lower
transcriptional activity and decreased levels of plasma Lp(a) [69]. The Precocious
Coronary Artery Disease study identified two more SNPs, rs3798220 and rs10455872,
which are located in the protease-like domain and the long intron of KIV7, respectively
[70]. Although the mechanism is unknown, these SNPs were both found to be causally
related to increased plasma Lp(a) levels and risk of coronary disease. Taken together, it has
been determined that apo(a) isoform size and specific variants within the LPA gene account
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for up to 90% of the differences in plasma Lp(a) concentrations observed between
individuals [21].

1.2.6

Lp(a) Metabolism

Although ample amounts of literature exist describing the sequence of the LPA gene and
the physical structure of Lp(a), there still remain many unanswered questions regarding
how and where Lp(a) is assembled, secreted and cleared from the circulation. These gaps
in knowledge have significantly hindered the developed of therapeutics to specifically
lower elevated plasma Lp(a) levels.

1.2.6.1

Lp(a) Biosynthesis and Secretion

The LPA gene, which encodes apo(a), is located on chromosome 6q26-27 and is most
highly expressed in the liver [71]. Lower amounts of apo(a) mRNA have also been
identified in the brain, lung, testes, and adrenal and pituitary glands [72]. Although apo(a)
is expressed in a variety of tissues, an elegant liver transplant study was able to show that
only apo(a) derived from hepatic tissues is incorporated into the Lp(a) particle. In this
study, it was noted that the recipient’s apo(a) isoform size on their circulating Lp(a)
changes to match that of the donor following liver transplantation [71].
The exact site of Lp(a) particle formation remains elusive. As mentioned previously, apo(a)
is transcribed and then translated into the ER where it matures and moves through the golgi
and secretory pathway. From here, it is still not well understood how and where this newly
translated apo(a) protein associates with an apoB-100 containing lipoprotein to form Lp(a).
Until recently, it was believed that newly synthesized apo(a) was freely secreted and would
assemble extracellularly with circulating LDL to form Lp(a) [73]. This idea was supported
by in vitro work in hepatocytes, where apo(a) appeared to assemble with LDL either in the
media or on the cell surface [74]. This notion of extracellularly Lp(a) assembly was further
supported when circulating Lp(a) complexes were isolated from apo(a) transgenic mice
following injection of human LDL-apoB-100 [75]. The extracellular assembly dogma has
been challenged by in vivo stable isotope studies in humans. Frischmann and colleagues
were able to show that the production rates of apo(a) and apoB-100 in Lp(a) were very
similar and took this as evidence of intracellular Lp(a) assembly [76]. However, it is
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important to remember that an intracellular covalent apo(a) and apoB-100 containing Lp(a)
complex has never been directly observed in any in vivo or in vitro work. The only evidence
of an intracellular covalent complex came from in vitro work in human hepatic cells where
a non-physiologically relevant apo(a) isoform size was used and expressed at nonphysiologically relevant levels [77].
The origin of the LDL component of Lp(a) is not well understood. Some studies have
shown that the FCR of apo(a) differs from that of LDL-apoB100, which might suggest that
apo(a) is exchanged between different apoB-100 containing lipoproteins [78]. However,
this could also be evidence of apo(a) and apoB-100 uptake and degradation or recycling to
form new Lp(a) particles. One study showed evidence of apo(a) being secreted on a
triglyceride-rich very low-density lipoprotein (VLDL) particles [79]. However, the general
consensus in the field is that Lp(a) does not arise from lipolysis of apo(a)-containing VLDL
particles [80]. The aforementioned metabolic labelling work by Frieschmann and
colleagues also showed that the secretion kinetics of apoB-100 that is in complex with
apo(a) is different from the secretion kinetics of apoB-100 in other lipoprotein particles.
Therefore, it seems plausible that there might exist a unique pool of apoB-100 containing
lipoproteins that are secreted from hepatocytes and destined for Lp(a) assembly [76].
Although very few studies have isolated intracellular covalent Lp(a) complexes [77], the
kinetic studies showing similarities between apoB-100 and apo(a) secretion and production
rates may serve as evidence of the existence of an intracellular non-covalent interaction
between these two lipoproteins. These kinetic studies, coupled with the inability to isolate
covalent Lp(a) complexes intracellularly, laid the foundation for the development of a twostep hypothesis for Lp(a) assembly (Fig. 1.4). The first step of Lp(a) assembly is believed
to involve an initial non-covalent interaction between apoB-100 and apo(a). The rationale
for this step developed from in vitro studies which showed that disruptions in the weak
lysine binding sites of apo(a) resulted in significant decreases in Lp(a) assembly [81].
Importantly, covalent complexes could still be isolated, just at much lower levels than
control [76]. As mentioned previously, apo(a) KIV5-8 each possess weak lysine binding
sites, and so it was initially thought that all of these domains were important for this first
step in Lp(a) assembly. However, it was later determined that only the weak lysine binding
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sites in KIV7 and KIV8 are required for this non-covalent interaction [82]. Specific
mutations to both the apo(a) KIV7 and KIV8 lysine binding sites resulted in a 13-fold
decrease in binding affinity for apoB-100 and a 75% reduction in Lp(a) particle formation
[82]. It was also determined that Lys680 and Lys690 in apoB-100 mediate this strong noncovalent interaction with the KIV7 and KIV8 domains of apo(a) [82]. Because these studies
show that mutations in the weak lysine binding sites in KIV7 and KIV8 result in decreased
efficiency of Lp(a) particle assembly, it has been hypothesized that this first step in Lp(a)
production is likely important to properly orient apo(a) and apoB-100 for step two.
Although the specific domains and residues involved with this step in Lp(a) formation are
well known, whether or not this interaction occurs inside the cell remains elusive [83].
Interestingly, it has recently been shown that specific LDL-lowering therapeutics designed
to inhibit apoB-100 maturation can also have effects on apo(a) and Lp(a) production and
secretion [84]. This has been interpreted as indirect evidence of an intracellular interaction
between apo(a) and apoB-100 and will be discussed in more detail below.
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Figure 1.4: Schematic representation of the postulated two-step mechanism of Lp(a)
assembly. Lp(a) biosynthesis takes place in hepatocytes. Assembly of Lp(a) involves the
association of apo(a) with an LDL-like lipid particle of unknown origin. The first step of
Lp(a) assembly is believed to involve a non-covalent interaction between Lys680 and Lys690
in apoB-100 and the KIV7 and KIV8 wLBS of apo(a). Disruption of the wLBS in KIV7 and
KIV8 through lysine or lysine analogs results in decreased efficiency of Lp(a) particle
assembly. It is not yet known whether the first step in Lp(a) biosynthesis is an intracellular
or extracellular event. The second step is thought to occur on the cell surface or in the
extracellular environment and involve the disulfide covalent linkage of a free cysteine in
the C-terminus of apoB-100 (possibly Cys4326 or Cys3734) with Cys4057 in KIV9 of apo(a).
A yet unknown extracellular enzyme with specific oxidase capacity appears to accelerate
the covalent linkage between apo(a) and apoB-100.
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The second step of Lp(a) assembly involves a disulfide covalent interaction between apo(a)
and apoB-100 (Fig. 1.4). As mentioned, very few studies have been able to isolate covalent
Lp(a) particles from cell lysates, and so it is generally accepted that this step occurs
extracellularly. The idea that covalent assembly of Lp(a) occurs outside of the cell is
strengthened by studies conducted in a cultured cell model that demonstrated a specific
oxidase activity in the cell medium which helps facilitate the covalent linkage between
apo(a) and apoB-100 [85]. The identity of this oxidase enzyme and how it interacts with
the assembling Lp(a) particle is not known. It has been reported that the free Cys4057 in
KIV9 is responsible for single disulfide covalent interaction with a cysteine in the Cterminus of apoB-100 [38]. However, there is conflicting evidence in the literature as to
which cysteine in apoB-100 is involved in covalent linkage with apo(a), although the
majority of evidence suggests a role for either Cys4326 or Cys3734 [86, 87].
In summary, Lp(a) assembly is thought to occur via a two-step process: an initial noncovalent interaction dependent on the weak lysine binding sites of apo(a) KIV7-8 followed
by a single disulfide covalent linkage between free cysteines in KIV9 of apo(a) and the
amino-terminus of apoB-100. The exact site of particle formation remains elusive. Whether
or not the first step occurs inside the cell remains to be determined, but if a non-covalent
interaction between apo(a) and apoB-100 is present intracellularly, then disruptions in the
secretion of apoB-100 would be expected to impact the secretion of apo(a) and vice versa.
Better understanding the molecular mechanisms involved in the biosynthesis and secretion
of Lp(a) will likely provide insight into potential therapeutic targets for drugs targeted to
specifically lower elevated levels of circulating Lp(a).

1.2.6.2

LDL-lowering Therapies & Insight into Lp(a) Assembly

As mentioned, it has recently been observed that certain pharmacological therapies
designed to lower plasma LDL-C levels, also appear to have effects on plasma Lp(a) levels.
Mipomersen is an antisense oligonucleotide directed against apoB-100 mRNA that
promotes the degradation of target mRNA by RNase H1 [88]. The idea to inhibit apoB100 secretion was motivated by studies of familial hypobetalipoproteinia (FHBL), an
inherited condition characterized by low levels of circulating apoB-100/LDL and
decreased arterial wall stiffness [89, 90]. By acting to decrease the production and secretion
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of apoB-100, it was thought that mipomersen might be able to mimic some of the protective
effects observed in FHBL patients. Early clinical trials showed that mipomersen could
lower plasma apoB-100 and LDL-C levels by 50% and 35%, respectively [91].
Interestingly, a recent study involving healthy volunteers showed that mipomersen is also
effective in lowering Lp(a) levels by 21% [92]. Importantly, changes in Lp(a) production
rates were strong predictors of Lp(a) reduction in some individuals [91]. Therefore,
mipomersen, a drug which affects the production rates of apoB-100, also appears to affect
the production rate of Lp(a).
Another LDL-lowering therapy that targets apoB-100 production and affects plasma Lp(a)
levels is lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor. MTP
localizes to the ER where its main role is to load neutral lipids, i.e. triglycerols and
cholesterol esters, to assembling apoB-containing lipoproteins [93]. The role of MTP in
lipoprotein assembly will be discussed in more detail below. Interest in inhibiting MTP to
treat elevated plasma cholesterol spurred from the discovery that genetic mutations in the
MTP gene led to abetalipoproteinemia [94]. Lomitapide was one of the first MTP inhibitors
to be discovered, and early phase 1 clinical trials in modestly hypercholesterolemic patients
showed that a daily oral dose of 100 mg could lower LDL-C by up to 85% [95].
Interestingly,
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hypercholesterolemia patients receiving either 40 mg per day lomitapide or control showed
not only a 40% reduction in LDL-C levels, but also a 13% reduction in plasma Lp(a) levels
[95].
Unfortunately, both mipomersen and lomitapide have quite extensive side-effect profiles,
and thus their use has been restricted to familial hypercholesterolemia (FH) patients or
other high-risk patients that cannot meet cholesterol goals on statins, cholesterol absorption
inhibitors, or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [95]. Both
mipomersen and lomitapide inhibit apoB-100 containing lipoprotein secretion, which has
in many cases been shown to result in increased hepatic fat content and increased serum
liver transaminase levels [95]. Although these therapeutics may not serve as realistic
treatment options for individuals with elevated Lp(a) levels because of their side-effect
profiles, they can be utilized in vitro to gain insight into the mechanisms of Lp(a)
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biosynthesis and secretion. Because lomitapide and mipomersen both function to decrease
apoB-100 production and secretion and also subsequently lower Lp(a) levels by an
unknown mechanism, they could serve to help identify whether or not an intracellular noncovalent interaction between apo(a) and apoB-100 exists in Lp(a) assembly. If a noncovalent interaction between apo(a) and apoB-100 does exist, then inhibiting apoB-100
mRNA translation with mipomersen, or inhibiting apoB-100 protein lipidation with
lomitapide might result in decreased apo(a) secretion and thus explain the observed
decreases in Lp(a) production rates associated with these two therapeutics. Assessments of
apo(a) secretion rates in the presence and absence of mipomersen and lomitapide would
help further support or refute this hypothesis.

1.2.6.3

Lp(a) Catabolism

Plasma Lp(a) clearance occurs almost exclusively in the liver, with minor amounts being
catabolized through the kidney [96]. It has been determined that the apo(a) component of
Lp(a) is the primary ligand for uptake, as co-injection of excess apo(a) with Lp(a) into mice
strongly inhibits plasma Lp(a) clearance [96]. Although a specific Lp(a) uptake receptor
has not yet been identified, multiple receptors with other defined ligands have shown to
bind to and facilitate the clearance of Lp(a). The LDL receptor (LDLR) [96], VLDL
receptor (VLDLR) [97], scavenger receptor class B member 1 [98], and the plasminogen
receptor family [99] have all been described as having roles in Lp(a) catabolism. It seems
likely that all of these receptors probably play some role in Lp(a) clearance, however the
relative contribution of each is not yet known. Interestingly, the statin class of drugs, which
lower plasma LDL-C levels through increasing the number of LDLR’s at the cell surface,
do not seem reduce plasma Lp(a) levels in most cases [100]. Therefore, it could be possible
that under normal physiological conditions, each of the aforementioned receptor types play
only minor roles in Lp(a) catabolism, and that it is the collective efforts of many different
receptors that facilitate adequate Lp(a) clearance.
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1.3 Proprotein Convertase Subtilisin/Kexin Type 9
1.3.1

Discovery & Defining Features

In 2003, PCSK9 was discovered and identified as the ninth member of the proprotein
convertase family of proteases [101]. Since the 1960’s it has been recognized that many
hormones and enzymes are first secreted as zymogens, or inactive precursors, that require
proteolytic cleavage to become active [102]. For this reason, it was hypothesized that
specific enzymes might be responsible for regulating these proteolytic conversions. In the
1990’s 8 enzymatic proteins, termed proprotein convertases (PC), were discovered to be
responsible for catalytic processing and activation of various hormones, metalloproteases,
growth factors, receptors, and surface glycoproteins [103].
The PCSK9 protein is a unique member of the PC family due to its atypical zymogen
activation activity [101]. Transcription and translation of the PCSK9 gene results in the
production of a 692 amino acid (AA) serine protease [104]. Within the ER, the newly
synthesized PCSK9 protein undergoes cleavage of its signal peptide (AA 1-30) [101]. In
order to exit the ER, this pro-PCSK9 (AA 31-692) must also cleave itself to release its
prosegment (AA 32-152), and in doing so becomes the mature PCSK9 enzyme (AA 153692) [101]. However, this self-cleaved prosegment becomes noncovalently bound to the
substrate binding active site of the mature PCSK9 enzyme, which effectively inhibits any
and all enzymatic activity [101]. In this way, PCSK9 is quite different from other members
of the PC family because it displays no zymogen activation activities [103]. Although
PCSK9 lacks zymogen activation activity, the protein has been observed to bind to specific
target proteins and direct them towards intracellular degradation [103].

1.3.2

The LDL-Receptor & PCSK9

The PCSK9 gene is most highly expressed in the liver and is located on chromosome 1p32,
a region that has been linked with FH [103]. For these reasons, it was hypothesized that
PCSK9 may have some role in cholesterol metabolism. In 2003, Abifadel and colleagues
discovered that specific gain-of-function mutations in the PCSK9 gene led to
hypercholesterolemia [105]. It was at this point that PCSK9 was recognized to have a role
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in lipid metabolism and became the third FH-associated locus, alongside the LDL-R gene
and the apoB-100 gene [103].
Cholesterol is a key membrane component of all cells in the human body. Cholesterol can
be obtained from the diet and transported in the circulation within chylomicrons or it can
be synthesized de novo. De novo synthesis of cholesterol occurs in liver hepatocytes and is
dependent on the activity of the rate-limiting hydroxy-3-methylglutaryl coenzyme A
reductase (HMG CoA-R) enzyme [106]. The cholesterol produced from this pathway is
packaged into triglyceride-rich VLDL particles and moves through the circulation to
supply cellular demands. After VLDL particles are stripped of their triglyceride
components by lipoprotein lipase, the cholesterol-rich remnant particle is remodelled by
the liver to form LDL [107]. The LDL particle supplies cholesterol to all cells of the body
through an interaction mediated through the LDL-R.
During periods of low intracellular cholesterol, cells of the body utilize a sensing
mechanism involving the sterol-regulatory element-binding protein (SREBP), which
facilitates increased expression of the LDL-R [108]. It should be noted here that the statin
class of drugs act to inhibit HMG CoA-R. This causes decreases in intracellular cholesterol
levels and results in SREBP-mediated increases in LDL-R levels and subsequent LDL-C
plasma clearance [109]. The interaction between the apoB-100 component of LDL with
the LDL-R at the cell surface triggers a receptor-mediated endocytosis event [110]. The
endocytic vesicle containing the LDL/LDL-R complex moves towards the endosome and
eventually fuses with the lysosome [110]. It is the low pH environment of the lysosome
that facilitates the release of cholesterol and triglycerides from particle to the cytosol for
cellular use [110]. This low pH environment also causes the dissociation of the LDL-R
from the LDL particle, which can then be recycled back to the cell membrane in order to
bind to and uptake more LDL [110].
The discovery of PCSK9 gave insight into another pathway for cholesterol regulation.
PCSK9 is a soluble protein that circulates at low abundance and can bind to the epidermal
growth factor-A (EGF-A) domain of the LDL-R [111]. Upon binding to the LDL-R at the
cell surface, PCSK9 induces endocytosis and the PCSK9/LDL-R complex moves towards
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the lysosome, much like the LDL/LDL-R complex pathway [110]. However, in the
presence of PCSK9, the LDL-R is not able to dissociate from the complex at low pH to be
recycled to the cell membrane [112]. Instead, through a yet unknown mechanism, the
binding of the PCSK9/LDL-R complex becomes stronger at low pH, and the LDL-R is
shuttled to the lysosome for degradation [113]. Therefore, by promoting LDL-R
degradation, PCSK9 acts to inhibit cellular cholesterol uptake, which subsequently
increases plasma LDL-C levels.
Recent evidence suggests that PCSK9 can also affect plasma LDL-C levels by augmenting
apoB-100 secretion. Sun and colleagues overexpressed human PCSK9 in three separate
mouse models and were able to consistently demonstrate significant increases in plasma
apoB levels in an LDL-R independent fashion [114]. In this same study, coimmunoprecipitation (co-IP) showed that direct interactions between apoB and PCSK9
exist in cell lysates [114]. Furthermore, pulse-chase studies conducted in C57BL/6 LDLR-/- mouse primary hepatocytes demonstrated that PCSK9 expression significantly
increased both the secretion and intracellular accumulation of apoB-100 and apoB-48
[114]. Therefore, it appears that PCSK9 also has an impact on apoB-containing lipoprotein
production through altering its secretion.

1.3.3

PCSK9 Inhibitors

Shortly after the discovery of PCSK9, it was determined that individuals with loss-offunction mutations in the PCSK9 gene had lifelong decreases in plasma LDL-C levels and
significant reductions in the incidence of atherosclerosis [115]. It was at this point that
pharmaceutical companies began to race to develop drugs that mimicked this PCSK9 lossof-function phenotype. The most promising and successful PCSK9 inhibiting drugs
manufactured to date are evolocumab and alirocumab, both of which are fully humanized
monoclonal antibodies that bind to PCSK9 and block its interactions with the LDL-R [116].
By inhibiting the PCSK9-mediated degradation of the LDL-R, these monoclonal
antibodies have proven to be effective in reducing plasma LDL-C levels by about 60%,
and risk of MI and stroke by about 20% after a 2-year treatment regimen [116].
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Interestingly, PCSK9 inhibitors have consistently been shown to also reduce Lp(a) levels
by up to 30% [117]. Although the mechanism underlying these reductions is not yet
understood, some have postulated that these decreases are due to PCSK9 inhibitormediated LDL-R up-regulation and subsequent increased Lp(a) catabolism. However,
many are skeptical of this explanation. Lp(a) has been shown to be cleared through the
LDL-R, but as mentioned earlier, this receptor likely only plays a minor role in Lp(a)
catabolism [118]. In support of the idea that PCSK9 inhibition reduces plasma Lp(a) levels
via a mechanism independent of the LDL-R, statins, which also augment LDL-C clearance
by increasing LDL-R levels, have in many cases not proven to be effective in lowering
Lp(a) levels [119]. These findings suggest that inhibition of PCSK9 may have additional
effects beyond the LDL-R, which may account for the observed decreases in plasma Lp(a).

1.3.4

PCSK9 & Lp(a) Metabolism

The aforementioned plasma Lp(a) reductions mediated by PCSK9 inhibitors have
motivated researchers in the field to understand how or if PCSK9 regulates Lp(a)
metabolism. Work in our lab has shown that the addition of PCSK9 to culture medium
inhibits Lp(a) internalization in HepG2 cells [120]. Although the LDL-R is not regarded as
a major route for Lp(a) clearance, the Lp(a) internalization inhibition mentioned above did
appear to be LDL-R dependent [120]. The effects of PCSK9-mediated Lp(a) internalization
inhibition could not be repeated in fibroblasts from FH patients lacking the LDL-R [120].
It could be possible that treatment of cells with high concentrations of exogenous PCSK9
can reduce LDL-R levels enough to observe decreases in Lp(a) internalization versus
control. Furthermore, all of the PCSK9 inhibitor studies that have demonstrated decreased
Lp(a) levels involve study subjects that are also receiving optimal statin therapy [121]. This
combination of treatments significantly increases the levels of LDL-R, and concomitantly
significantly decreases its LDL ligand. These conditions decrease any potential
competition between Lp(a) and LDL for the LDL-R, which may allow the LDL-R to
become a more significant Lp(a) clearance receptor, and account for the observed plasma
Lp(a) lowering in the PCSK9 inhibitor studies.
Interestingly, recent evidence suggests that PCSK9 does not significantly impact Lp(a)
catabolism but rather enhances Lp(a) production and secretion. Villard and colleagues used
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primary human hepatocytes to show that treatment of cells with increasing concentrations
of PCSK9 resulted in a 3-fold increase in apo(a) secretion [122]. Moreover, this increase
was completely reversed with alirocumab treatment [122]. Therefore, rather than
decreasing Lp(a) uptake, it appears that decreases in plasma Lp(a) levels observed in
PCSK9 inhibitor-treated individuals is mediated through decreased Lp(a) secretion.
However, it has previously been demonstrated that PCSK9 cannot associate with apo(a)
[120]. If this holds to be true, then the question of how PCSK9 increases apo(a) secretion
can be raised. Intriguingly, in vitro studies have demonstrated that PCSK9 treatment does
in fact increase apoB-100 secretion [122]. Therefore, it could be postulated that if an
intracellular non-covalent interaction existed between apoB-100 and apo(a), then PCSK9mediated increases in apoB-100 secretion may indirectly account for the observed
increases in apo(a) secretion. Continued assessments of the secretion and intracellular
accumulation patterns of both apo(a) and apoB-100 in the presence or absence of PCSK9
may help provide further mechanistic understandings of the steps involved in Lp(a)
production. Furthermore, these studies would help elucidate how PCSK9 inhibition by
alirocumab and evolocumab specifically lowers plasma Lp(a).

1.4 Microsomal Triglyceride Transfer Protein
1.4.1

Structure & Function

MTP is a heterodimeric protein complex that resides in the ER [123]. The smaller 55-kDa
“P” subunit has been identified as ubiquitously expressed ER protein disulfide isomerase
(PDI) [124]. Non-covalently bound to the P subunit is the larger 97-kDa “M” subunit [124].
The binding of the M subunit to the P subunit physically obstructs its active site, and thus
MTP does not retain the ability to catalyze disulfide bonds [125]. The M subunit possesses
the unique ability to transfer neutral lipids (triglycerides and cholesterol esters) to specific
targets [126]. Interestingly, the P subunit does not have any capacity to transfer lipids, and
it has been demonstrated that various missense mutations to the P subunit do not impact
MTP’s ability to transfer lipids [126]. However, addition of agents that disrupt the
heterodimer complex results in aggregation of the M subunit and complete loss of lipid
transfer activity, suggesting that the P subunit has a structural stability role [127].
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Abetalipoproteinemia is a condition characterized by the inability to absorb dietary fats
and fat-soluble vitamins, and is coupled with the complete lack of plasma apoB-containing
lipoproteins. MTP was recognized as an important regulator of lipoprotein synthesis when
it was discovered that individuals with abetalipoproteinemia had specific loss-of-function
mutations in MTP-encoding genes. The liver and intestine are the major sites of MTP
expression. Importantly, these organs are also responsible for the production of apoBcontaining VLDL and chylomicron particles, respectively. The M subunit of MTP contains
three major structural domains: a N-terminal -barrel domain, a middle -helical domain,
and a C-terminal -sheet [93]. The N-terminal B-barrel is responsible for interaction with
the N-terminus of apoB, the middle -helical domain interacts with both apoB and the P
subunit, while the C-terminal -sheet is crucial for the lipid binding and lipid transfer
activities of MTP [93].

1.4.2

MTP & ApoB-containing Lipoprotein Assembly

MTP was recognized as an important lipid transfer molecule after it was discovered that
specific missense mutations in the M subunit lipid transfer domain precipitated the
complete lack of circulating apoB in abetalipoproteinemia patients. The dependency of
apoB production and secretion on MTP activity was further demonstrated in an elegantly
designed in vitro study. ApoB and MTP were co-expressed in non-hepatic cells that do not
naturally express these proteins [128]. In the absence of MTP, apoB was synthesized but
was then subsequently degraded and not secreted [128]. In contrast, when apoB and MTP
were coexpressed in this cell model, apoB was both synthesized and secreted [128].
The binding of MTP to apoB is hypothesized to serve two functions [129]. Firstly, it is
believed that MTP binding is critical for the prevention of apoB degradation [129]. It is
known that newly synthesized apoB undergoes dislocation from the ER membrane and is
subsequently degraded by proteasomes if it is not assembled into a lipoprotein [130].
Researchers have postulated that by binding to nascent apoB, MTP acts to prevent its
dislocation from the ER membrane, thereby inhibiting its proteosomal degradation [129].
Secondly, it is believed that MTP plays a crucial role in primordial lipoprotein assembly
through its lipid transfer activities. MTP-mediated lipidation of apoB-peptides renders
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them secretion-competent. Although this process is still not well understood, it is assumed
that free MTP in the ER binds to nascent apoB and then proceeds to extract lipids from the
ER membrane and transfer them to apoB [129]. It has also been hypothesized that rather
than transferring lipids to apoB from the ER membrane, MTP associates with a lipid droplet
in the ER lumen, which it then donates to nascent apoB [129]. This droplet would become
a lipid core for which the nascent apoB could encircle [129]. Regardless of the mechanism,
it is clear that the physical binding and transfer of neutral lipids between apoB and MTP in
the ER is essential for the production and secretion of apoB-containing lipoproteins.

1.4.3

Implications with Lp(a)

As discussed previously, MTP has become a lipid lowering target to treat diseases
characterized by high circulating levels of apoB-containing lipoproteins [131]. However,
because of MTP’s important role as a regulator of lipoprotein secretion, studies have shown
that individuals taking MTP inhibiting medications, such as lomitapide, experience
increased hepatic fat retention and increased plasma liver transaminase levels [132]. These
findings have limited lomitapide use to specific cases where other treatment alternatives
have proven to be ineffective. Despite its side-effect profile, lomitapide has sparked interest
and conversation amongst researchers due to its ability to lower plasma Lp(a) levels. As
mentioned, clinical trials have shown that lomitapide can both lower plasma LDL by up to
40% and plasma Lp(a) by up to 13% [93]. However, the mechanism by which lomitapide
lowers plasma Lp(a) remains unknown.
It has been hypothesized by some groups that apo(a) is secreted freely on its own and later
interacts with circulating LDL or LDL at hepatocyte cell surfaces to form Lp(a) [73]. If
this dogma is correct, then lomitapide-mediated inhibition of apoB-containing lipoprotein
production would lower Lp(a) levels as a consequence of lower levels of circulating LDL
being available for free apo(a) to bind to. However, previously mentioned kinetic studies
have shown that apo(a) and apoB-100 production rates are quite similar, and that there
might be a unique pool of apoB-100 destined for Lp(a) assembly [76]. These studies have
suggested the idea that the initial steps in Lp(a) production may involve a non-covalent
intracellular interaction between apo(a) and apoB-100. In vitro analysis of apo(a) and
apoB-100 secretion in cells treated with lomitapide may help to elucidate the assembly and
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production of Lp(a). Unlike apoB-100, apo(a) does not undergo lipidation in the ER, and
thus its production does not appear to be MTP-dependent. Therefore, decreased secretion
of apo(a) in response to lomitapide treatment may be interpreted as indirect evidence of an
apo(a)/apoB-100 intracellular interaction that is critical for apo(a) secretion. Conversely,
if apo(a) production does not involve intracellular interactions with apoB-100, then
lomitapide treatment would not be expected to impact apo(a) secretion.

1.5 Sortilin
1.5.1

Genome-Wide Association Studies

Atherosclerosis is a multifactorial disease that involves the contribution of genetic and
environmental risk factors. Although atherosclerosis has been studied for over a century,
CVD still remains the leading cause of death in Western countries. This reflects the
complexity of the disease process and emphasizes the need for recognition of novel risk
factors and genetic mutations that contribute to the pathophysiology of CVD. Genomewide association (GWA) studies are observational studies that are used to identify genetic
associations on an epidemiological basis, typically by analyzing single nucleotide
polymorphisms (SNPs) [133]. These genetic studies provide identification of risk alleles
associated with complex diseases, like neurodegenerative and cardiovascular diseases
[134]. GWA studies of large populations with wide ethnicity and age demographics have
been conducted to identify specific genes or loci associated with elevated plasma LDLcholesterol (LDL-C) phenotypes. These studies have served to identify numerous SNP
variants throughout the human genome that are strongly associated with LDL-C levels. Not
surprising, the vast proportion of these SNPs were found to occur in the genes encoding
PCSK9, apoB, the LDL-R, and other protein players known to be causally involved in
plasma cholesterol regulation. Interestingly, the 1p13 chromosomal region was identified
as being more strongly associated with LDL-C levels than any other locus in the human
genome. Despite not having any known role in lipid metabolism, this locus has been
independently associated with CAD and MI. Importantly, a noncoding rs12740374 variant
in the 1p13 locus has been identified as the causal SNP responsible for modulating plasma
LDL-C levels and MI risk [134]. In depth analysis has revealed that individuals with the
minor allele variant at this locus have significantly elevated expression of the sortilin-
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encoding SORT1 gene.

In fact, compared to major allele homozygotes, individuals

homozygous for the minor allele variant have 12-fold higher SORT1 expression levels.
Interestingly, these elevated expression levels occurred exclusively in the liver. Further
examination has shown that rs12740374 alters the binding of the liver specific C/EBP
transcription factor; the major allele disrupts C/EBP binding, which has been demonstrated
to decrease SORT1 expression [134]. After determining that a causal relationship exists
between rs12740374 and LDL-C levels, this same research group used an adeno-associated
virus approach to specifically overexpress SORT1 in mouse hepatocytes. In vivo analysis
showed that SORT1 overexpression resulted in significantly decreased total plasma
cholesterol levels [134]. Therefore, due to its interaction with C/EBP and increased
expression of SORT1, the minor allele was assumed to be cardioprotective. However, as
will be discussed below, there is much controversy surrounding the true role of sortilin in
lipid metabolism.

1.5.2

Structure & Function

Sortilin is a multi-ligand sorting receptor involved in the intracellular transport of proteins
such as brain-derived neurotrophic factor, Glut4, and lipoprotein lipase [135]. Sortilin is
characterized by an extracellular vacuolar protein sorting 10 (VPS10) domain and thus
belongs to the VPS10 domain family of receptors [135]. The characteristic VPS10 ligand
binding domain is homologous to the yeast VPS10P sorting receptor and is present in all
receptors within this family. The four other members of this receptor family are SorLA,
sorCS1, sorCS2 and sorCS3. The VPS10 domain, responsible for ligand binding, is 700
amino acids in length and forms a ten-bladed -propeller physical structure [136]. The
sortilin receptor also consists of a transmembrane domain, as well as a sorting and
internalization motif-containing cytoplasmic tail [137].
Sortilin is a membrane-embedded receptor that is present in small amounts on the cell
surface, but mainly localizes to the membrane of the trans-Golgi network (TGN) [138].
The TGN is a major center for trafficking and recycling of various different proteins, which
is consistent with the hypothesized role of sortilin as an intracellular sorting receptor [138].
Depending on the molecule and the metabolic demands of the cell, proteins within the TGN
can be sorted for secretion, packaged within endosomes, or targeted to the lysosome for
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degradation [138]. To prevent premature ligand binding, sortilin is first synthesized as a
propeptide [139]. Upon entering the TGN, sortilin is subsequently cleaved by furin, which
enables it to become the mature receptor with full ligand binding capacity [139]. There are
three proposed trafficking pathways for sortilin and the VPS10 family of receptors (Fig.
1.5): (i) The complex of sortilin and its ligand can move through the constitutive secretory
pathway from the TGN towards the cell membrane. Depending on the properties of the
protein, the ligand can either become a plasma membrane-embedded receptor or be
secreted to the extracellular environment [140, 141]. (ii) Plasma membrane-embedded
sortilin can bind to extracellular ligands and facilitate clathrin-dependent internalization.
The internalized complex moves from the cell membrane to endosomes [137], where it can
then be trafficked towards the TGN for ligand recycling [142], or towards the lysosome for
ligand degradation [143]. (iii) Sortilin and its protein ligand can be exported from the TGN
and secreted together into the extracellular environment within secretory granules or
exosomes [144, 145]. In each case, the pathway taken is dependent on the binding of
specific adaptor proteins to the trafficking motifs within sortilin’s cytoplasmic tail [137].
Sortilin is most highly expressed in the brain and spinal cord, and was first identified as a
neurotransmitter receptor and important regulator of neuronal survival and degradation
[146]. It has been hypothesized that sortilin and other members of the VPS10 family
contribute to neuronal death and survivability by regulating the intracellular transport of
neurotransmitters and neurotrophic factors towards or away from lysosomal degradation
(123). Furthermore, sortilin and its relatives have been implicated in the pathogenesis of
Alzheimer’s disease after studies showed that improper processing of amyloid precursors
by sortilin-related receptors facilitates the A amyloid accumulation characteristic of the
disease [146]. Lower levels of sortilin expression have also been observed in the kidneys,
heart, liver, adipose tissue and skeletal muscle [147, 148]. As previously mentioned,
another known ligand for sortilin is Glut4, the insulin-regulated glucose transporter [149].
Adipocytes and skeletal muscles cells store Glut4 intracellularly within Glut4 storage
vesicles (GSVs). During periods of elevated plasma glucose levels, insulin mediated
signalling regulates the shuttling of GSVs towards the cell membrane, which subsequently
results in increased cellular glucose uptake [149]. Importantly, in vitro studies have
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demonstrated that sortilin is a key component of GSVs that regulates the trafficking of
Glut4 to the cell surface in response to insulin signaling [149]. These findings have
suggested a role for sortilin as a regulator of insulin-mediated glucose uptake, and
potentially implicate the sorting receptor in the pathogenesis of diabetes mellitus.
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Figure 1.5: The proposed intracellular trafficking pathways of VPS10 family receptors.
Trafficking of VPS10 domain receptors begins with cleavage of the propeptide in the TGN
(1) and is thought to occur through at least 3 pathways: (i) Sortilin and its protein ligand
can move through secretory granules (2) and the complex can be secreted together within
extracellular vesicles. (ii) Sortilin and its ligand can move through constitutive secretory
vesicles (3) towards the plasma membrane (4). Depending on the properties of the ligand,
it can become an embedded plasma membrane receptor or be secreted to the extracellular
environment. Sortilin can also become an embedded plasma membrane receptor, or can be
cleaved by metalloproteases and -secretases to become a soluble protein (5). (iii) As a
plasma membrane receptor, sortilin can bind to extracellular protein ligands and facilitate
their internalization through AP-2/clathrin dependent endocytosis (6). Sortilin can direct
the internalized protein towards the TGN for recycling (7,8) or towards the multi-vesicular
body (9) and lysosome (10) for degradation. In each case, the pathway taken is dependent
on the binding of specific adaptor proteins to the trafficking motifs within sortilin’s
cytoplasmic tail. Adapted from [150].
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1.5.3

Sortilin’s Enigmatic Role in LDL Metabolism

Several genome-wide studies conducted over the past 10 years have identified sortilin as
an important regulator of lipid metabolism. Confusingly, numerous experimental
approaches have demonstrated an association between sortilin knockdown and sortilin
overexpression with increased plasma LDL-C levels. Although it is clear that sortilin
modulates LDL metabolism, the direction of the relationship between sortilin expression
and plasma LDL levels remains highly controversial.
Adeno-associated virus (AAV) expression of the SORT1 gene in humanized mice livers by
Musunuru and colleagues resulted in a significant decrease in plasma LDL-C levels [134].
These reductions in LDL-C levels were attributable to decreased secretion of the LDL
precursor molecule, VLDL [134]. In further support of these findings, AAV-mediated
SORT1 liver overexpression in C57BL/6 mice fed high-fat diets resulted in markedly
reduced plasma triglyceride and apoB-100 levels [151]. Importantly, the reductions in
LDL-C observed in these studies appears to involve autophagy-dependent lysosomal
degradation of apoB-100 [152]. It has been shown that autophagy formation inhibitors
diminish the decreases in triglyceride and apoB-100 secretion associated with sortilin
overexpression [152]. Furthermore, specific mutations within the cytoplasmic tail domain
of sortilin inhibits its ability to induce the autophagic flux of apoB-100 [152]. It has also
been shown, using surface plasma resonance studies, that high affinity binding exists
between sortilin and apoB-100 [153, 154]. Taken together, the inverse correlation observed
between SORT1 expression and LDL-C levels in the aforementioned rodent studies appears
to be dependent on high affinity binding between sortilin and apoB-100, followed by
degradation of VLDL through the autophagy-lysosomal pathway.
The overexpression models that associated sortilin with increased apoB-100 secretion led
to the hypothesis that sortilin knockout or knockdown would increase levels of plasma
LDL-C and VLDL secretion. However, Kjolby and colleagues found that sortilin-deficient
mice had significantly reduced levels of plasma LDL-C [155]. Furthermore, this decrease
in plasma LDL-C observed in SORT1 knockout mice was coupled with lower levels of
VLDL secretion [155]. Importantly, this group also used an adenovirus system to
specifically overexpress sortilin in mice hepatocytes. However, unlike Musunuru’s group,
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Kjolby and colleagues observed significant increased lipoprotein secretion and plasma
LDL-C levels in response to hepatic sortilin overexpression [155]. Immunofluorescent
detection of apoB in SORT1-/- and SORT1+/+ mouse hepatocytes was also performed. In the
sortilin-deficient mice, apoB immunostaining demonstrated dispersed staining throughout
the cell, characteristic of ER localization [155]. Conversely, adenovirus-mediated sortilin
overexpression in mice hepatocytes was associated with apoB accumulation in the trans
golgi [155]. Therefore, Kjolby and colleagues concluded that sortilin acts to increase
VLDL secretion and plasma LDL-C concentrations by way of an intracellular association
between apoB and sortilin within the golgi, which facilitates the movement of apoBcontaining lipoproteins through the secretory pathway.
The exact role of sortilin in lipid metabolism remains controversial. The relationship
between sortilin, VLDL secretion, and LDL-C levels appears to be quite complex, and it
has been postulated that the directionality of the relationship can be influenced by
intracellular and extracellular metabolic conditions, as well as the experimental model
used. For example, Kjolby’s group used mice that had a double knockout of both the LDLR and sortilin and demonstrated a direct relationship between SORT1 expression and
plasma cholesterol levels [155]. Interestingly, Linsel-Nitschke and colleagues
demonstrated an inverse relationship between sortilin and LDL-C that appeared to involve
LDL clearance [156]. This group reported that sortilin overexpression in human embryonic
kidney 293 (Hek 293) cells resulted in elevated uptake of LDL particles, potentially
through a mechanism involving modulation of the LDL-R [156]. Therefore, it could be
possible that sortilin plays a role in both apoB-containing lipoprotein catabolism and
secretion. If this were the case, then Kjolby’s LDL-R knockout mouse model may have
highlighted sortilin’s role as a regulator of apoB-100 secretion, while masking its role in
LDL clearance. It could also be possible that the extracellular lipid environment alters the
directionality of sortilin’s relationship with plasma cholesterol levels. For example, recent
evidence suggests that apoB-100 secretion from SORT1-/- mice differs if the mouse is on a
control diet or a high-fat diet [157]. In line with this idea, it has also been hypothesized that
the use of specific mouse models may be limited in their ability to demonstrate the true
nature of the relationship between sortilin and LDL-C. For example, the aforementioned
studies conducted by Musunuru and colleagues utilized humanized apoB-100-expressing
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mice to more closely mimic the human plasma lipid profile. However, it is possible that
the artificial lipid profile of humanized mice alters the normal physiological metabolism of
lipoproteins. The expression of human apoB-100 in mice may have stressed the intrinsic
lipoprotein biosynthesis pathways which subsequently led to sortilin targeting of apoB-100
to the lysosome rather than towards secretion.
In summary, although GWA studies have implicated the SORT1-encoding locus as a
regulator of plasma LDL-C levels and risk factor for CVD, sortilin’s role in lipoprotein
metabolism has not yet been fully elucidated. Preliminary cellular and animal model
studies have demonstrated conflicting results in regard to the direction of the relationship
between sortilin and plasma LDL-C levels. These contradictory data suggest that sortilin’s
role in the regulation of lipid metabolism may not be unidirectional. It appears that the
relationship between sortilin and plasma LDL levels may be influenced by the extracellular
environment, hepatic lipid content, metabolic requirements, and intracellular stress.

1.5.4

Sortilin & Lp(a)

Nearly 90% of the variation in Lp(a) levels observed between individuals is due to genetic
differences in the apo(a)-encoding LPA gene [157]. Therefore, roughly 10% of plasma
Lp(a) variation can be attributable to variations elsewhere in the genome. In order to
identify LPA-independent genetic effects on Lp(a) levels, Zekavat and colleagues have
recently performed deep-coverage whole genome sequencing (WGS) in 8392 individuals
of European and African descent [158]. As mentioned, rs12740374 SORT1 variants have
been causally associated with LDL-C levels. Interestingly, Zekavat and colleagues also
found an association between rs12740374 with plasma Lp(a) levels [158]. This plasma
Lp(a) modulation was determined to be independent of changes in LDL-C, suggesting that
sortilin is a novel receptor for Lp(a) metabolism [158].
Previous work in our lab conducted by Gemin and colleagues (unpublished data) has
demonstrated that sortilin overexpression enhances apo(a) secretion from human hepatoma
cell lines stably expressing apo(a). Conversely, sortilin knockdown, as well as mutation of
sortilin’s cytoplasmic targeting sequences, was shown to decrease apo(a) secretion.
Intriguingly, co-IP studies demonstrated that sortilin is unable to directly associate with
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with apo(a). Furthermore, mutation of the wLBS in KIV7 and KIV8, postulated to be
important for the initial non-covalent interactions with apoB-100, prevented sortilin from
affecting apo(a) secretion. As mentioned previously, however, high affinity binding has
been observed between sortilin and apoB-100 [153, 154]. Taken together, this evidence
suggests that a noncovalent intracellular interaction exists between apo(a) and apoB-100,
and that sortilin increases apo(a) secretion indirectly through increasing apoB-100
secretion. However, this theory is challenged by previously mentioned in vivo and in vitro
work that suggests an inverse relationship exists between SORT1 expression and LDL-C
levels. For example, Musunuru’s group showed that AAV sortilin expression in mouse
livers resulted in decreased apoB-100 secretion [134]. If sortilin decreases apoB-100
secretion and cannot directly associate with apo(a), it would be expected that SORT1
overexpression would indirectly facilitate decreased apo(a) secretion. However, it is
important to note that mice do not express LPA. Furthermore, for unknown reasons, all of
the hepatocyte cell lines previously described do not endogenously produce Lp(a). If an
intracellular interaction exists between apo(a) and apoB-100, this interaction could
potentially alter sortilin’s physical association with apoB-100, and thus have an impact on
apoB-100 secretion. The lack of apo(a) expression and Lp(a) production in commonlyused animal models and established cell lines is another limiting factor in the study of
sortilin and its modulation of lipoprotein metabolism. To further understand the
relationship between sortilin and apoB-containing lipoprotein metabolism, it will be
important to assess apoB-100 secretion from cells in the presence and absence of apo(a)
coexpression.
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1.6 Rationale, Objectives & Hypotheses
It is now known that elevated plasma Lp(a) concentrations represent the single most
prevalent inherited risk factor for CVD [21]. However, the absence of available clinical
therapeutics to lower plasma Lp(a) concentrations reflects the lack of fundamental
understanding of the cellular pathways regulating Lp(a) metabolism. Since it is believed
that anabolism rather than catabolism is the primary determinant of plasma Lp(a)
concentrations, it is imperative that the production and secretion of this lipoprotein be
understood. It has been suggested that the formation of Lp(a) occurs in a two-step process.
The first step likely involves a weak, non-covalent interaction between apoB-100 and the
wLBS in KIV7 and KIV8 of apo(a), and precedes the second step which involves the
covalent linkage of a free cysteine in apoB-100 with a free cysteine in KIV9 of apo(a).
Although the majority of evidence suggests that the covalent step of Lp(a) formation occurs
in the extracellular environment, the location of non-covalent association between apo(a)
and apoB-100 remains enigmatic. The primary objective of this study was to use an in vitro
model to asses if a noncovalent intracellular interaction exists between apo(a) and apoB100 in Lp(a) assembly. We hypothesize that if an intracellular non-covalent interaction
exists between apo(a) and apoB-100, then proteins involved in regulating apoB-100
secretion will also modulate apo(a) secretion and Lp(a) production. To address this
hypothesis, three specific aims have been developed:
The first aim is to determine the mechanism by which sortilin modulates the secretion of
apo(a). Previous work in our lab has shown that sortilin cannot directly associate with
apo(a) but can significantly increase its secretion. Therefore, it has been postulated that
apo(a) binds to apoB-100 in the cell, and sortilin-mediated increases in apoB-100 secretion
indirectly increase apo(a) secretion. However, in vivo sortilin overexpression studies in
mice hepatocytes lacking apo(a) expression have been associated with decreased apoB-100
secretion. If apo(a) and apoB-100 interact intracellularly, then we hypothesize that cells
coexpressing apo(a) and apoB-100 may have different apoB-100 secretion patterns in
response to sortilin overexpression than cells lacking apo(a) expression. To further our
understanding of sortilin’s role in Lp(a) metabolism, we collaborated with Dr. Robert
Hegele and performed deep sequencing of the SORT1 locus in a large cohort of individuals
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with elevated Lp(a) levels. We identified 7 unique SORT1 polymorphisms in 9 individuals
that had Lp(a) levels in the top 5th percentile of the general population. Importantly, these
amino acid substitutions all occurred within sortilin’s VPS10 ligand binding domain. We
hypothesize that by transfecting these human sortilin polymorphisms into HepG2 cells and
then assessing apo(a) secretion, we will gain further insight into the mechanistic role of
sortilin in Lp(a) metabolism.
The second aim is to determine the role of PCSK9 in Lp(a) production. Alirocumab and
evolocumab are PCSK9 inhibitors used to treat elevated LDL-cholesterol but have also
been shown to decrease Lp(a) levels by 20% to 30%. Although the main mechanism of
action for PCSK9 inhibitors is to decrease LDL-receptor degradation, the LDL-receptor is
not thought to be significantly involved in Lp(a) metabolism under normal physiological
conditions. These findings provide evidence of a unique role for PCSK9 in Lp(a)
metabolism. If PCSK9 has a role in modulating Lp(a) biosynthesis, we hypothesize that
treating HepG2 human hepatoma cells with purified PCSK9 may induce changes in the
secretion of apo(a), potentially through alterations in apoB-100 secretion.
The third aim is to determine if MTP plays a role in Lp(a) biosynthesis and secretion.
Lomitapide is an MTP-inhibitor used to treat elevated levels of plasma LDL cholesterol.
Interestingly, lomitapide treatment has also been shown to significantly reduce plasma
Lp(a). The transfer of lipids from MTP to apoB-100 in the ER is essential for the assembly
and secretion of all apoB-containing lipoproteins. If a noncovalent intracellular interaction
exists between apo(a) and apoB100 during Lp(a) biosynthesis, we hypothesize that MTP
inhibition with lomitapide will affect apo(a) secretion, potentially through modulation of
apoB-100 secretion.
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Chapter 2

2

Methods
2.1 Cell Culture

All cell lines were grown at 37C with 95% humidity and 5% CO2. Human hepatocellular
carcinoma (HepG2) cells were purchased from American Type Culture Collection (ATCC)
and maintained in Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12
(DMEM/F12; Gibco) supplemented with 10% Fetal Bovine Serum (FBS; VWR).
Wild-type (WT) HepG2 cells and HepG2 cells stably expressing a 17-Kringle (17K) apo(a)
isoform were utilized in this study. Construction of the 17K apo(a) plasmid (17K-pRK5)
was performed as previously described [159]. The 17K apo(a) isoform is a physiologically
relevant apo(a) variant that possesses KIV1, KIV3-10, KV, the inactive protease and 8 KIV2
domain repeats. The stably expressing 17K apo(a) HepG2 cell line was constructed as
follows: HepG2 cells were seeded at 75% confluency and transfected using MegaTran 1.0
transfection reagent (Origene) according to manufacturer’s protocol. Cells were transfected
with 1g of 17K apo(a) plasmid and 0.2g of a neomycin resistance-encoding plasmid.
After 24 hours of transfection, cells were allowed to recover in fresh medium for 24 hours.
Media was then replaced again and supplemented with 0.4mg/l Geneticin® selective
antibiotic (G418 sulfate; Thermo Fisher Scientific). Successful transfection was evaluated
using dilution cloning and western blot analysis.

2.2 Construction of Sortilin Expression Plasmids
The WT human sortilin expression system used in this study was generously provided by
Dr. Nabil Seidah (McGill University). This pcDNA 3.1C/Myc-His vector contains the
human sortilin cDNA with a C-terminal Myc-His tag. In collaboration with Dr. Robert
Hegele (Robarts Research Institute) and with informed consent, deep sequencing of the
SORT1 locus was undertaken in 1740 patients with dramatically elevated Lp(a) levels [160,
161]. Seven sortilin amino-acid substitution variants were found to be associated with
Lp(a) levels in excess of the top 5th percentile of the general population: I124V, K205N,
K302E, F404Y, E444Q, E447G, and V650M. Each missense mutation was constructed
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using the Q5® Site-Directed Mutagenesis Kit (NEB) according to manufacturer’s protocol.
In each case, the WT sortilin pcDNA 3.1C/Myc-His expression plasmid was used as a
template. The primers and PCR conditions used for mutagenesis are shown in Table 2.1
and Table 2.2, respectively. Each mutation was verified by DNA sequencing using the
Sort_Seq_2 primer (5’-TCCACGTTTCAACAGATCAAG-3’) at the Robarts Research
Institute sequencing facility.
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Table 2.1. Primers used for generation of human sortilin polymorphic variants. Only
sense strands are shown. In each case, the mutated nucleotide is bolded, and the mutated
codon is underlined. Each primer was constructed by Integrated DNA technologies.
Mutant

Sequence (Sense Strand)

Sort-I124V

5’-CACTGGGGTCGTTCTAGTCTTG-3’

Sort-K205N

5’-ATTTTGCGAATAATTTTGTGCAAAC-3’

Sort-K302E

5’-TATTGGTGTGGAAATCTACTCATTTG-3’

Sort-F404Y

5’-GAGACGGACTATACCAACGTG-3’

Sort-E444Q

5’-GAGGAAGCCTCAAAACAGTGAATGTG-3’

Sort-E447G

5’-GAAAACAGTGGATGTGATGCTACAGC-3’

Sort-V650M

5’-CAAGTCATCCATGTGTCAGAATGG-3’

Table 2.2. PCR exponential amplification for human sortilin mutagenesis using BioRad T100 Thermal Cycler.
Step

Temperature (C)

Time

Initial Denaturation

98

30 sec

25 Cycles

98

10 sec

66 (annealing)

10-30 sec

72

200 sec

72

120 sec

4-10

-

Final Extension
Hold
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2.3 Transient Transfections
For human sortilin pulse-chase analysis experiments, 17K apo(a)-expressing HepG2 cells
(17K HepG2 cells) were seeded into 6-well tissue culture plates (Thermo Fisher Scientific)
and grown to 70% confluency. Fresh medium was given to cells 4 hours prior to
transfection. Cells were then either transfected with 1g of empty-vector pcDNA 4A/MycHis, WT sortilin pcDNA 3.1C/Myc-His, Sort-I124V pcDNA 3.1C/Myc-His, Sort-K205N
pcDNA 3.1C/Myc-His, Sort K302E pcDNA 3.1C/Myc-His, Sort-F404Y pcDNA
3.1C/Myc-His, Sort-E444Q pcDNA 3.1C/Myc-His, Sort-E447G pcDNA 3.1C/Myc-His or
Sort-V650M pcDNA 3.1C/Myc-His using linear polyethylenimine (PEI; Sigma) according
to manufacturer’s protocol. Transfection was allowed to proceed overnight, and then cells
were given fresh medium for 24 hours prior to the start of the experiment.
For specified pulse-chase experiments involving PCSK9 or lomitapide treatment, a HepG2
cell line transiently expressing a 17K apo(a) isoform lacking the wLBSs in KIV7 and KIV8
(17K7,8 HepG2 cells) was used. WT HepG2 cells were grown to 70% confluency in 6well tissue culture plates. Fresh medium was given to cells 4 hours prior to transfection.
Cells were transfected with 1g of 17K7,8 apo(a)-pRK5 using linear PEI according to
manufacturer’s protocol. Construction of the 17K7,8 apo(a)-pRK5 expression plasmid was
performed as previously described [159]. Transfection was allowed to proceed overnight,
and then cells were given fresh medium for 24 hours prior to the start of the experiment.

2.4 Construction and Purification of PCSK9
The PCSK9-pcDNA 4C vector was constructed and stably expressed in human embryonic
kidney 293 (HEK293) cells as previously described [160]. Stably-expressing cells were
seeded into triple flasks and grown in Opti-MEM (Life Technologies). Conditioned
medium was then harvested every three days and supplemented with polymethylsulfonyl
fluoride (PMSF) to a final concentration of 1mM. To purify PCSK9, the harvested medium
was applied to a nickel-Sepharose excel column (GE Healthcare) as previously described
[160]. Eluted protein fractions (4 column volumes) were then dialyzed extensively against
PCSK9 storage buffer (25mM HEPES pH 7.9 containing 0.1mM CaCl2, 150mM NaCl,
and 10% glycerol). After dialysis, samples were concentrated using PEG 20000 (Sigma)
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followed by further dialysis against PCSK9 storage buffer. Purified protein concentrations
were assessed using the bicinchonicic acid assay (BCA assay; Pierce). SDS-PAGE was
followed by silver stain analysis to assess protein purity. The harvested protein was run at
a concentration of 25ng/ul next to 25ng/ul of a PCSK9 standard. The purified PCSK9
protein was then aliquoted and stored at -80C until use.

2.5 Pulse-Chase Analysis
For the sortilin overexpression studies, apo(a) or apoB-100 secretion was analyzed from
17K HepG2 cells and WT HepG2 cells using pulse-chase studies. Cells were grown in
DMEM/F12 supplemented with 10% FBS. The HepG2 cells were seeded into 6-well plates
at 3 x 105 cells/well and allowed to attach overnight prior to transfection. At a confluency
of 70%, cells were transfected with either 1g of empty-vector pcDNA 4A/Myc-His, WT
sortilin pcDNA 3.1C/Myc-His, Sort-I124V pcDNA 3.1C/Myc-His, Sort-K205N pcDNA
3.1C/Myc-His, Sort K302E pcDNA 3.1C/Myc-His, Sort-F404Y pcDNA 3.1C/Myc-His,
Sort-E444Q pcDNA 3.1C/Myc-His, Sort-E447G pcDNA 3.1C/Myc-His or Sort-V650M
pcDNA 3.1C/Myc-His. Following overnight transfection, cells were given fresh medium
and allowed to recover for 24 hours before labelling.
For the PCSK9 and lomitapide (Sigma) treatment studies, apo(a) and apoB-100 secretion
were analyzed from HepG2 cells expressing 17K apo(a) or the 17K7,8 apo(a) variant using
pulse-chase studies. For analysis of 17K apo(a) and apoB-100 secretion, 17K HepG2 cells
were seeded in 6-well plates at 3 x 105 cells/well, allowed to attach overnight, and then
grown for 48 hours in DMEM/F12 supplemented with 10% FBS prior to the start of the
experiment. For analysis of 17K7,8 apo(a) and apoB-100 secretion, WT HepG2 cells were
seeded into 6-well plates at 3 x 105 cells/well and allowed to attach overnight prior to
transfection. Cells were then transfected with 1g of the 17K7,8 apo(a)-pRK5 expression
plasmid. Following overnight transfection, cells were given fresh DMEM/F12
supplemented with 10% FBS and allowed to recover for 24 hours prior to the start of the
experiment.
On the morning of the experiment, the cells were given fresh DMEM/F-12 containing 10%
FBS and 0.4 mM oleic acid complexed to 1% BSA (w/v) for 4 hours prior to labelling. For
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the PCSK9 and lomitapide treatment studies, the DMEM/F-12 containing 10% FBS and
0.4mM oleic acid was also supplemented with either PCSK9 or lomitapide. Following the
4-hour incubation, cells were washed with 1 mL of phosphate buffered saline (PBS) and
then 1mL of cysteine and methionine free Dulbecco’s Modified Eagle Medium (DMEM;
Gibco), without serum, was added for 1 hour. After 1 hour, cells were labelled with 200
Ci/well [35S]-cysteine/[35S]-methionine (Perkin Elmer Life Sciences) for 1 hour. Cells
were then washed once with 1 mL of PBS and incubated in 500 L serum-containing
DMEM/F-12 supplemented with 0.4 mM oleic acid for 0, 30, 60, 120, or 360 minutes. For
the PCSK9 and lomitapide treatment studies, the chase medium was also supplemented
with either PCSK9 or lomitapide. At each of the aforementioned chase times, conditioned
medium (500 L) was collected and supplemented with 1% protease inhibitor cocktail
(Sigma). Cells were then washed once with ice-cold PBS containing 50 mM epsilonaminocaproic

acid

(-ACA)

and

subsequently

lysed

with

ice-cold

radioimmunoprecipitation buffer (RIPA; 50 mM Tris pH 7.4, 20mM EDTA, 150 mM
NaCl, 0.1% (w/v) SDS, and 1% (w/v) sodium deoxycholate) supplemented with 1%
protease inhibitor. Cell lysates and media samples collected at the aforementioned chase
times were then stored on ice prior to clarification by centrifugation for 6 minutes at 15,000
rpm to remove cellular debris.
Following centrifugation, samples were pre-cleared with 30 L of gelatin-agarose (Sigma)
for 3 hours at 4C with gentle shaking. Samples were then centrifuged for 2 minutes at
5000 rpm to pellet the gelatin-agarose and supernatants were exposed to saturating
quantities (1:500) of anti-apo(a) monoclonal (1-4; made in-house using r-apo(a) as the
antigen) or anti-apoB-100 polyclonal (Millipore) primary antibody overnight at 4C with
gentle shaking. After overnight incubation with primary antibody, 50 L of protein Gagarose beads (Invitrogen) was added to samples for 3 hours at 4C with gentle shaking.
Media and lysate samples were then centrifuged for 1 minute at 3000 rpm. Each pellet was
washed 3 times with 500 L ice-cold RIPA buffer supplemented with 1% protease
inhibitor. In each case, the pellet was gently resuspended in RIPA buffer prior to
centrifugation for 1 minute at 3000 rpm. After the third wash, pellets were resuspended in
2x SDS sample buffer (250 mM Tris pH 6.8, 4% (w/v) SDS, 40% (v/v) glycerol, and
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0.001% (w/v) bromophenol blue), supplemented with 7 L of 100 mM dithiothreitol
(DTT), briefly centrifuged, boiled for 7 minutes and then pulse-centrifuged again.
Samples were then subjected to SDS-PAGE on 6% polyacrylamide gels. Following
electrophoresis, gels were fixed in 100 mL of fixing solution (methanol:glacial acetic
acid:H2O, 40:10:50) with gentle shaking for 25 minutes. Gels were then rinsed briefly with
milli-Q H2O and then incubated in 100 mL of Amplify solution (GE Healthcare) with
gentle shaking for 30 minutes. Next, the gels were subjected to 100 mL of 1M sodium
salicylate containing 3 drops of 100% glycerol with gentle shaking for 30 minutes.
Following the washing steps, the gels were dried using a gel dryer (BioRad Model 583) on
the ‘Page’ setting for 1 hour and 15 minutes at 80C. After the gels had dried, they were
exposed to a phosphor K screen in the dark at room temperature for 96 hours and then
screens were imaged using the Molecular Dynamics Storm 820 phosphoimager
(Amersham). Resultant bands were quantified by densitometry using the ImageJ 1.49v
software. The mature and immature forms of intracellular apo(a) were each quantified
separately and then summed.

2.6 Western Blotting
To analyze sortilin expression, cell lysates were subjected to SDS-PAGE on 10%
polyacrylamide gels. All samples were prepared as 50 µL aliquots, re-suspended in 12.5
µL 4X SDS sample buffer and supplemented with 5 µL of 100 mM DTT. Samples were
then boiled for 7 minutes at 100 degrees Celsius and pulse-centrifuged before being
subjected to SDS-PAGE for 1.5 hours at 120 volts. The gels were transferred in ice cold
transfer buffer (25mM Tris pH 7.8, 1.92 M glycine, 10% (v/v) Methanol) for 1.5 hours at
120 volts onto PVDF membranes (Millipore) and then blocked in 15 mL of 50 mM Tris
pH7.6 containing 150 mM NaCl, 0.2% (v/v) Tween-20 (TBST) supplemented with 5%
(w/v) powdered non-fat milk for 1 hour at room temperature while gently shaking.
Following blocking, membranes were then incubated with either goat-anti-human sortilin
(R&D Systems) or mouse-anti-human β-actin (Novus Biologicals) overnight in the same
blocking buffer at 4 degrees Celsius while gently shaking. After overnight incubation, the
membranes were washed three times in TBST for 10 minutes each while gently shaking.

48

The membranes were then incubated for 1 hour at room temperature while gently shaking
with either sheep-anti-mouse secondary antibody (GE Healthcare) or mouse-anti-goat
secondary antibody (Santa Cruz). The membranes were then washed again three times in
TBST for 10 minutes each at room temperature while gently shaking. Resultant bands were
visualized with SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo
Scientific) using a FluorChem Q Imager (Alpha Innotech) and densitometric quantification
of resulting bands was performed using Alpha View software (Alpha Innotech).

2.7 Statistical Analysis
All data are presented as mean  standard error of the mean (SEM). Statistical analyses
were performed with the GraphPad Prism version 7 software program. For the human
sortilin polymorphic variant pulse-chase studies, differences between samples were
characterized using one-way analysis of variance (ANOVA) with a Tukey’s multiple
comparisons test (*p<0.05). The apoB-100 pulse-chase studies performed in WT HepG2
cells and 17K HepG2 cells in response to WT sortilin overexpression were evaluated for
differences using a two-tailed Student t-test assuming unequal variances (*p<0.05). For the
lomitapide treatment studies, apo(a) data were analyzed using one-way ANOVA with a
Tukey’s multiple comparisons test (*p<0.05), while apoB-100 data were analyzed using a
two-tailed Student t-test assuming unequal variances (*p<0.05). Apo(a) and apoB-100
pulse-chase data for the PCSK9 treatment studies were analyzed using a two-tailed Student
t-test assuming unequal variances (*p<0.05).
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Chapter 3

3

Results
3.1 Human sortilin polymorphic variants increase apo(a)
intracellular abundance and apo(a) secretion from
HepG2 cells

A causal relationship between circulating Lp(a) levels and the SORT1 rs12740374 variant
has been recently been established through deep-coverage WGS. Previous work in our
laboratory has demonstrated that sortilin overexpression stimulates apo(a) secretion and
increases apo(a) intracellular abundance in 17K HepG2 cells. To help further understand
sortilin’s role in Lp(a) metabolism, we collaborated with Dr. Robert Hegele and performed
deep sequencing of the SORT1 locus in a large cohort of individuals with elevated Lp(a)
levels. Intriguingly, we identified 7 unique SORT1 polymorphisms that were present in
individuals with Lp(a) levels in the top 5th percentile of the general population. The I124V,
K205N, K302E, F404Y, E444Q, and E447G amino acid substitutions were found to occur
in sortilin’s ten-bladed -propeller ligand binding domain. The V650M variant, which is
the only variant found outside of the -propeller domain, occurs within a highly conserved
10CC module found adjacent to the transmembrane domain [162]. However, the
mechanism by which these specific variants increase plasma Lp(a) had not been evaluated
at the cellular level. Here, we transiently transfected 17K HepG2 cells with expression
vectors containing WT sortilin, empty vector control (pcDNA), sort-I124V, sort-K205N,
sort-K302E, sort-F404Y, sort-E444Q, sort-E447G or sort-V650M and then analyzed
apo(a) secretion using pulse-chase studies (Fig. 3.1 A-B). Western blot analysis of cellular
lysates revealed that each sortilin mutant was expressed at similar levels (data not shown).
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Figure 3.1: Effect of human sortilin polymorphisms on apo(a) secretion, apo(a)
intracellular abundance, and rate of apo(a) maturation. Pulse-chase analysis of HepG2
cells stably expressing the 17K apo(a) isoform and transiently expressing either wild-type
sortilin (WT), sortilin I124V, sortilin K205N, sortilin K302E, sortilin F404Y, sortilin
E444Q, sortilin E447G, sortilin V650M, or the corresponding empty vector control
(pcDNA). Cells were starved in Cys/Met free media for one hour, pulse labelled with 35SCys/Met for one hour, and subsequently incubated for 0 minutes, 120 minutes and 360
minutes in unlabelled complete medium. Cell media (A) and lysates (B) were collected
from cells transfected with wild-type sortilin, empty vector pcDNA and each of the 7
mutants at the indicated times of chase. Samples were then subjected to apo(a)
immunoprecipitation, and then analyzed by 6% SDS-PAGE and fluorography. The top
band (550kDa) in the fluorograms represents a mature, fully glycosylated form of apo(a),
while the bottom band (450kDa) represents an immature, hypo-glycosylated form of
apo(a). Densitometric band analysis was conducted using the ImageLab 5.2 software,
normalized to the maximum observed density for WT sortilin, and plotted as a function of
time. (C) Percentage of mature apo(a) formed was calculated according to the formula: %
Mature apo(a) = [mature apo(a)] / [(mature apo(a)) + (immature apo(a))] × 100. (D)
Western blot analysis of sortilin expression in HepG2 cells ectopically expressing emptyvector control (pcDNA), wild-type (WT) sortilin, Sort-I124V, Sort-K205N, Sort-K302E,
Sort-F404Y, Sort-E444Q, Sort-E447G, or Sort-V650M. The presented data correspond to
the mean  SEM of at least 3 independent experiments. Significance compared to empty
vector is represented by asterisks where *p<0.05, **p<0.01, ***p<0.001 and
****p<0.0001. Significance compared to wild-type sortilin is represented by daggers,
where †p<0.05 and ††p<0.01. Significance was determined using one-way ANOVA.
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The representative fluorograms in Fig. 3.1 A show that mature apo(a) (550 kDa) could not
be observed in the medium at 0 minutes, but was detectable at 120 minutes and 360
minutes. As demonstrated in Fig. 3.1 A, an apparent trend exists between sortilin
overexpression and increased apo(a) secretion. Although no statistical significance was
observed, transfecting 17K apo(a)-expressing HepG2 cells with wild-type sortilin resulted
in a 4.4-fold and a 4.2-fold increase in apo(a) secretion at 120 minutes and 360 minutes,
respectively, versus empty vector control (pcDNA). At the chase time of 120 minutes, each
human sortilin polymorphic variant, with the exception of the sort-I124 (p=0.280) and sortE447G (p=0.548) variants, were able to significantly increase apo(a) secretion versus
pcDNA (Fig. 3.1 A). Apo(a) secretion was most greatly augmented at t=120 minutes by
the sort-K302E and sort-F404Y variants. The K302E variant significantly increased apo(a)
secretion in comparison to both empty vector control (p=0.004) and wild-type sortilin (Fig
3.1 A). The F404Y variant also significantly increased apo(a) secretion versus the empty
vector control (p=0.0002) and wild-type sortilin (p=0.01). When compared to the pcDNA
control, overexpression of each of the 7 human sortilin polymorphic variants significantly
increased apo(a) secretion at the 360-minute chase time. The K302E, F404Y, and E444Q
variants each resulted in significantly increased apo(a) secretion (p=0.0019; p=0.0012;
p=0.0062, respectively) compared to wild-type sortilin overexpression at the
corresponding time.
Within the cell, apo(a) can be observed as both an immature (450 kDa) and mature (550
kDa) form (Fig. 3.1 B). The immature form represents newly synthesized, hypoglycosylated apo(a) in the ER. The mature form has undergone addition of N-linked and
O-linked glycans in the ER and golgi compartments, respectively, and represents the
secreted form of apo(a) [35]. As can be observed in the representative fluorogram, the
different maturation states of apo(a) can be observed as two separate bands. The lower
band can be observed at all 3 chase times, and represents the immature and incompletely
glycosylated form of apo(a). The top band represents the mature, fully glycosylated,
secreted form of apo(a), and is identical in in mobility to the apo(a) detected from
conditioned medium samples (Fig. 3.1 A). The mature form of apo(a) was not detectable
in cell lysates until the 120-minute chase time, which corresponds to the appearance of
apo(a) in the conditioned medium.
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As demonstrated in Fig. 3.1 B, an apparent trend exists between sortilin overexpression
and increased apo(a) intracellular abundance. Although not statistically different, wild-type
sortilin overexpression resulted in a 1.7-fold and a 1.4-fold increase in intracellular apo(a)
abundance at the chase times of 0 minutes and 120 minutes, respectively, versus control
pcDNA. At time zero of the chase period, each of the 7 human sortilin polymorphic
variants, with the exception of sort-E447G, significantly increased apo(a) intracellular
abundance compared to the empty vector (Fig. 3.1 B). Apo(a) intracellular abundance was
most greatly augmented by sort-K302E and sort-F404Y, which were the variants also
associated with the greatest increases in apo(a) secretion. Sort-K302E significantly
increased apo(a) intracellular abundance when compared to both pcDNA and wild-type
sortilin (Fig. 3.1 B). Similarly, sort-F404Y significantly increased apo(a) intracellular
abundance versus both pcDNA and wild-type sortilin. No significant differences in apo(a)
intracellular abundance were observed between pcDNA, wild-type sortilin, or each of the
7 sortilin variants at both the 120 and 360-minute chase points. For each of the 7 sortilin
variants, quantitative analysis of the cellular lysate fluorograms showed that there were no
significant differences in the rate of conversion from immature to mature apo(a) when
compared to pcDNA or wild-type sortilin (Fig. 3.1 C).
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3.2 Sortilin overexpression in HepG2 cells modulates
apoB-100 secretion and intracellular abundance
The nature of the relationship between sortilin expression and apoB-100 secretion has
proven to be quite complex. Interestingly, previous co-IP work in our lab demonstrated
that sortilin can physically associate with apoB-100 but not apo(a), and that sortilin’s
effects on apo(a) metabolism were diminished in apo(a) variants lacking the wLBS in
KIV7,8. Taken together, it appears that sortilin indirectly increases apo(a) secretion,
potentially through a mechanism involving augmentation of apoB-100 secretion and an
intracellular interaction between apo(a) and apoB-100. To test the validity of this
hypothesis, we used our stably expressing 17K apo(a) HepG2 cells transiently transfected
with wild-type sortilin. We then used pulse-chase studies to analyze apoB-100 secretion
and intracellular abundance. As previously mentioned, the direction of the relationship
between sortilin expression and apoB-100 secretion remains very controversial. Our
hypothesis that sortilin indirectly increases apo(a) secretion through augmenting apoB-100
secretion has been challenged by in vivo rodent studies, which have demonstrated that
sortilin overexpression in hepatocytes is associated with decreased apoB-100 secretion.
However, mouse hepatocytes do not express apo(a), and it could be possible that apo(a)
and apoB-100 coexpression impacts the nature of the relationship between sortilin
overexpression and apoB-100 secretion. To assess this hypothesis, we also utilized wildtype HepG2 cells, which do not express apo(a). We transiently transfected these cells with
wild-type sortilin or empty vector control (pcDNA), and then assessed apoB-100 secretion
and intracellular abundance using pulse-chase studies.
In line with the aforementioned rodent hepatocyte findings, Fig. 3.2 A (left) demonstrated
that sortilin overexpression in WT HepG2 cells resulted in significantly decreased apoB100 secretion. The representative fluorogram shows that apoB-100 could be initially
visualized in small amounts in the conditioned medium of WT HepG2 cells transfected
with empty vector starting at the 30-minute chase time and then gradually accumulated
over time. ApoB-100 could also be observed in trace amounts starting at 30 minutes in the
conditioned medium of WT HepG2 cells transiently transfected with sortilin. However,
WT HepG2 cells transfected with sortilin secreted significantly less apoB-100 at 120
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minutes and 360 minutes versus WT HepG2 cells transfected with pcDNA control.
Intriguingly, Fig. 3.2 A (right) demonstrates that sortilin overexpression in HepG2 cells
stably expressing 17K apo(a) resulted in significantly increased apoB-100 secretion. The
representative fluorograms for the 17K apo(a) HepG2 cells display a double banding
pattern. The top band is consistent with apoB-100 mobility, while the bottom band is
consistent with mature apo(a) mobility (550 kDa), as observed in Fig 3.1 A and B. In 17K
HepG2 cells transfected with pcDNA or sortilin, apoB-100 could be observed in small
amounts in cultured medium as early as 30 minutes of chase. However, 17K cells
transfected with sortilin demonstrated significantly increased secretion of apoB-100 at 60
minutes, 120 minutes and 360 minutes versus 17K HepG2 cells transfected with pcDNA
control. Although the apo(a) band could not be completely resolved in each replicate,
qualitative analysis demonstrated that sortilin overexpression was associated with
increased apo(a) secretion, similar to what was observed in Fig. 3.1 A.
As demonstrated in Fig. 3.2 B (left), sortilin overexpression in WT HepG2 cells resulted
in significantly decreased intracellular abundance of apoB-100 at 0 minutes, 30 minutes
and 60 minutes of chase versus pcDNA control. Conversely, sortilin transfection increased
apoB-100 intracellular abundance in 17K HepG2 cells (Fig. 3.2 B, right). At 0 minutes and
30 minutes of chase, sortilin transfection significantly increased apoB-100 intracellular
abundance versus pcDNA control. Therefore, it appears that sortilin overexpression
facilitates increased apoB-100 secretion and intracellular abundance in HepG2 cells stably
expressing 17K apo(a). However, in the absence of apo(a) coexpression (WT HepG2 cells),
our data indicate that sortilin overexpression results in decreased apoB-100 secretion and
intracellular abundance.
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Figure 3.2: Effect of sortilin overexpression on apoB-100 secretion and intracellular
abundance in the presence or absence of apo(a) coexpression. Pulse-chase analysis of
HepG2 cells stably expressing the 17K apo(a) isoform and wild-type HepG2 cells lacking
apo(a) expression. Cells were transiently transfected with wild-type sortilin or the
corresponding empty vector control (pcDNA). Cells were pre-incubated for 4 hours in
complete media containing 0.4mM BSA-conjugated oleic acid. Cells were then starved in
-Cys/Met free media for one hour, pulse labelled with 35S-Cys/Met for one hour, and
subsequently incubated for 0 minutes, 30 minutes, 60 minutes, 120 minutes and 360
minutes in unlabelled complete media containing 0.4mM BSA-conjugated oleic acid. Cell
Lysate samples were collected from cells transfected with wild-type sortilin or empty
vector pcDNA at the indicated times of chase. Samples were then subjected to apoB
immunoprecipitation, and analyzed by 6% SDS-PAGE and fluorography. (A) Media
samples collected at the indicated times of chase. The lower band (550 kDa) represents a
mature, fully glycosylated form of apo(a), while the upper sharp band represents apo-B100.
(B) Lysate samples collected at the indicated times of chase. The visible band represents
mature apo-B100. Densitometric band analysis was conducted using ImageJ software,
normalized to the maximum observed density for pcDNA, and plotted as a function of time.
The presented data corresponds to the means  SEM of 3 or 4 independent experiments.
Significance compared to empty vector pcDNA is represented by asterisks where *p<0.05,
and **p<0.01.
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3.3 PCSK9-mediated modulation of apo(a) secretion from
HepG2 cells is dependent on KIV7,8 weak lysine
binding sites
As mentioned, inhibition of PCSK9 by Alirocumab and Evolocumab has been associated
with decreased plasma Lp(a) levels. Furthermore, PCSK9 has recently been implicated as
a regulator of apoB-100 metabolism after PCSK9 knockout in mice resulted in significantly
decreased apoB-100 secretion [163]. For these reasons, we postulated that PCSK9 may
modulate Lp(a) biosynthesis and secretion. To test this hypothesis, we treated 17K HepG2
cells with PCSK9 or storage buffer, and then analyzed apo(a) secretion and intracellular
abundance with pulse-chase studies (Fig. 3.3 A; left). As demonstrated by the
representative fluorogram, PCSK9 or storage buffer treatment resulted in apo(a)
accumulation in the conditioned medium beginning at the 30-minute chase time. However,
compared to treatment with storage buffer control, 17K HepG2 cells treated with PCSK9
had significantly increased apo(a) secretion at the 120-minute and 360-minute chase times.
Analysis of 17K HepG2 cell lysates demonstrated that PCSK9 treatment resulted in
increased intracellular abundance of apo(a). Similar to Fig. 3.1 B, apo(a) can be observed
as both an immature and mature form within cell lysates (Fig. 3.3 B). Treatment of 17K
HepG2 cells with PCSK9 resulted in significantly increased intracellular abundance of
apo(a) at the 0-minute and 30-minute chase times compared to treatment with storage
buffer control (Fig. 3.3 B; left).
To determine if the PCSK9-mediated increases in apo(a) secretion are dependent on
interactions with apoB-100, we utilized HepG2 cells expressing the 17K7,8 apo(a) variant.
It has previously been demonstrated that the wLBS in KIV7,8 is important for facilitating
noncovalent interactions with apoB-100 [81]. Therefore, if the observed effects of PCSK9
on apo(a) secretion are mediated indirectly through modulation of apoB-100 metabolism,
disruption of the wLBS in apo(a) should elucidate this. As demonstrated in Fig. 3.3 A
(right), treatment of cells expressing the 17K7,8 apo(a) variant with PCSK9 did not affect
17K7,8 apo(a) secretion versus control. In line with the fluorographs observed for the 17K
HepG2 cells (Fig. 3.3; left), PCSK9 or storage buffer treatment of the 17K7,8 apo(a)
HepG2 cells resulted in 17K7,8 apo(a) accumulation in conditioned medium beginning at
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the 30-minute chase time. However, unlike the 17K HepG2 cells, PCSK9 treatment of the
17K7,8 apo(a) HepG2 cells did not significantly increase 17K7,8 apo(a) accumulation in
the conditioned medium versus control (Fig. 3.3 A; right). 17K7,8 apo(a) HepG2 cellular
lysates were also assessed to determine the effects of PCSK9 on 17K7,8 apo(a) intracellular
abundance. Again, similar to Fig. 3.1 B, 17K7,8 apo(a) can be observed as both an
immature hypo-glycosylated form (upper band), and a higher fully glycosylated form
(higher band). As demonstrated in the representative fluorogram (Fig. 3.3 B; right) 17K7,8
apo(a) was visible in its immature form starting at time 0, and then as both a mature and
immature form from 30-360 minutes. However, densitometric analysis of cellular lysates
demonstrated that PCSK9 treatment did not significantly affect the intracellular abundance
of 17K7,8 apo(a) versus control (Fig. 3.3 B; right).
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Figure 3.3: Treating HepG2 cells with PCSK9 increases wild-type apo(a) secretion and
intracellular abundance but does not affect secretion and intracellular abundance of an
apo(a) variant lacking the weak lysine binding sites in KIV7 and KIV8. Pulse-chase
analysis of HepG2 cells stably expressing 17K apo(a) and HepG2 cells transiently
expressing △7,8 LBS apo(a) following treatment with 20μg/mL of PCSK9 or control. Cells
were first pre-incubated for 4 hours in complete media containing 0.4mM BSA-conjugated
oleic acid in the presence or absence of 20μg/mL PCSK9. Cells were then starved in
Cys/Met free media for one hour, pulse labelled with 35S-Cys/Met for one hour, and
subsequently incubated for 0 minutes, 30 minutes, 60 minutes 120 minutes and 360 minutes
in unlabelled complete medium containing 0.4mM BSA-conjugated oleic acid in the
presence or absence of 20μg/mL PCSK9. Conditioned medium and cellular lysate samples
were collected from cells treated with or without PCSK9 at the indicated times of chase.
Samples were then subjected to apo(a) immunoprecipitation, and then analyzed by 6%
SDS-PAGE and fluorography. The lower band (450kDa) represents an immature hypoglycosylated form of apo(a), while the higher band (550kDa) represents a mature, fully
glycosylated form of apo(a). (A) Media samples of 17K apo(a) HepG2 cells (left) and
17K7,8 apo(a) HepG2 cells (right) treated with or without PCSK9 at the indicated times of
chase. (B) Lysate samples of 17K apo(a) HepG2 cells (left) and 17K7,8 apo(a) HepG2 cells
(right) treated with or without PCSK9 at the indicated times of chase. Densitometric band
analysis was conducted using ImageJ software, normalized to the maximum observed
density for control, and plotted as a function of time. The presented data correspond to the
means  SEM of 3 or 4 independent experiments. Significance compared to control is
represented by asterisks where *p<0.05, and **p<0.01.
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3.4 PCSK9 treatment increases apoB-100 secretion from
HepG2 cells independent of interactions with apo(a)
As demonstrated in Fig. 3.3, PCSK9-mediated increases in apo(a) secretion were
dependent on the wLBS in KIV7,8, which are the domains shown to be involved in
facilitating noncovalent interactions with apoB-100 [81]. To gain further insight into how
PCSK9 treatment increases apo(a) secretion, we repeated the experiment in the same cell
types but then subjected our samples to apoB-100 immunoprecipitation. Figure 3.4 (A)
illustrates that treatment of HepG2 cells exogenously with PCSK9 increases apoB-100
secretion. PCSK9 treatment of 17K HepG2 cells significantly increased apoB-100
secretion at the 60-minute and 120-minute chase times compared control (Fig. 3.4 A; left).
ApoB-100 secretion was maximally increased from 17K HepG2 cells by PCSK9 at the
360-minute chase time (Fig. 3.4 A; left). To determine if the same pattern of apoB-100
secretion existed in cells expressing an apo(a) variant unable to noncovalently interact with
apoB-100, we repeated the experiment in 17K7,8 apo(a)-transfected HepG2 cells. As
demonstrated in Fig. 3.4 A (right), apoB-100 secretion was significantly increased in
17K7,8 apo(a)-transfected HepG2 cells after 60-minutes, 120-minutes, and 360-minutes of
chase versus control. Comparisons of the maximal apoB-100 secretion intensity (t=360
minutes) in the 17K HepG2 cells and 17K7,8 HepG2 cells demonstrate that PCSK9 was
able to augment apoB-100 secretion to a greater degree in the 17K HepG2 cells (Fig. 3.4
A). Therefore, the presence of the wLBS in KIV7,8 of apo(a) appeared to affect the
relationship between PCSK9 treatment and apoB-100 secretion.
Cellular lysates were also analyzed to determine if the wLBS in KIV7,8 can affect the
intracellular abundance of apoB-100 in response to PCSK9 treatment (Fig. 3.4 B). In both
the 17K HepG2 cells treated with or without PCSK9 and the 17K7,8 HepG2 cells treated
with or without PCSK9, apoB-100 could be visualized in the representative fluorograms
from 0 minutes of chase to 360 minutes of chase (Fig. 3.4 B). PCSK9 treatment of 17K
HepG2 cells significantly increased the intracellular abundance of apoB-100 at the 0minute and 30-minute chase times versus control (Fig. 3.4 B; left). The intracellular
abundance of apoB-100 was also significantly increased by PCSK9 treatment in the 17K7,8
HepG2 cells at the 0-minute and 30-minute chase times versus control (Fig. 3.4 B; right).
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Interestingly, when comparing PCSK9 treatment in 17K HepG2 cells and 17K7,8 HepG2
cells, the intracellular abundance of apoB-100 appeared to be maintained at higher levels
throughout the chase in cells expressing the apo(a) variant lacking the wLBS in KIV7,8. At
the 60-minute chase time, the intracellular abundance of apoB-100 in 17K7,8 HepG2 cells
treated with PCSK9 appeared to be much greater than that control, although this effect was
not significant (Fig. 3.4 B; right). Conversely, apoB-100 intracellular abundance in 17K
HepG2 cells treated with PCSK9 trended much more closely to the intracellular abundance
of 17K HepG2 cells treated with control (Fig. 3.4 B; left). In summary, PCSK9 treatment
increased apoB-100 secretion and intracellular abundance regardless of the apo(a) species
being expressed, however a trend existed between PCSK9 and prolonged apoB-100
intracellular abundance in HepG2 cells expressing the apo(a) variant lacking the wLBS in
KIV7,8.
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Figure 3.4: PCSK9 treatment increases apoB-100 secretion and intracellular abundance
in HepG2 cells independent of the apo(a) species being coexpressed. Pulse-chase analysis
of HepG2 cells stably expressing 17K apo(a) and HepG2 cells transiently expressing △7,8
LBS apo(a) following treatment with 20μg/mL of PCSK9 or control. Cells were preincubated for 4 hours in complete medium containing 0.4mM BSA-conjugated oleic acid
in the presence or absence of 20μg/mL PCSK9. Cells were then starved in Cys/Met free
medium for one hour, pulse labelled with 35S-Cys/Met for one hour, and subsequently
chased for 0 minutes, 30 minutes, 60 minutes 120 minutes and 360 minutes in unlabelled
complete media containing 0.4mM BSA-conjugated oleic acid in the presence or absence
of 20μg/mL PCSK9. Conditioned medium and cellular lysate samples were collected from
cells treated with PCSK9 or control at the indicated times of chase. Samples were then
subjected to apoB-100 immunoprecipitation, and then analyzed by 6% SDS-PAGE and
fluorography. (A) Media samples of 17K apo(a) HepG2 cells (left) and 17K7,8 apo(a)
HepG2 cells (right) treated with or without PCSK9 at the indicated times of chase. (B)
Lysate samples of 17K apo(a) HepG2 cells (left) and 17K7,8 apo(a) HepG2 cells (right)
treated with or without PCSK9 at the indicated times of chase. Densitometric band analysis
was conducted using ImageJ software, normalized to the maximum observed density for
control, and plotted as a function of time. The presented data correspond to the mean 
SEM of 3 or 4 independent experiments. Significance compared to control is represented
by asterisks where *p<0.05, and **p<0.01.
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3.5 Lomitapide treatment inhibits apo(a) secretion from
HepG2 cells in a dose-dependent manner
The transfer of lipids onto apo-B100 through the actions of MTP is essential for the
biosynthesis and secretion of VLDL particles. Since VLDL is considered the precursor
molecule for LDL, therapeutics that target MTP, such as lomitapide, have been designed
to lower plasma LDL-C levels. Interestingly, lomitapide treatment has also been observed
to lower Lp(a) levels through an unknown mechanism. We treated HepG2 cells with
lomitapide and performed pulse-chase studies to analyze how inhibition of MTP affects
apo(a) secretion (Fig. 3.5 A). Furthermore, we utilized HepG2 cells expressing the wildtype 17K apo(a) isoform and cells expressing the 17K7,8 apo(a) to determine if an
intracellular interaction between apo(a) and apoB-100 impacts lomitapide’s ability to
modulate apo(a) metabolism. The representative fluorograms show that apo(a) was
detectable in conditioned medium of both 17K and 17K7,8 HepG2 cells and across all
treatment groups from 30-360 minutes of chase (Fig. 3.5 A), which is in line with the
secretion patterns of apo(a) observed in Fig. 3.3. As demonstrated in Fig. 3.5 A (left; blue
line), treatment of 17K HepG2 cells with 5 nM of lomitapide did not significantly affect
apo(a) secretion. However, compared to control, a trend of decreased apo(a) secretion in
response to 5 nM of lomitapide treatment was evident. Analysis of 17K HepG2 cells treated
with 10 nM of lomitapide showed that apo(a) secretion was significantly decreased at the
120-minute chase time compared to control (Fig. 3.5 A; left, green line). Treatment of 17K
HepG2 cells with 10 nM of lomitapide did not significantly affect apo(a) secretion at the
0, 30, 60- and 360-minute chase times versus control. However, a trend between 10 nM
lomitapide treatment and decreased apo(a) secretion at those time points could again be
observed. As demonstrated in Fig. 3.5 A (left; red line), treatment of 17K HepG2 cells with
20 nM of lomitapide significantly decreased apo(a) secretion at the 360-minute chase time
compared to 0 nM control. Apo(a) secretion from 17K HepG2 cells was maximally
inhibited by 20 nM of lomitapide at the 120-minute chase time versus control. Furthermore,
at the 120-minute chase time, 20 nM of lomitapide significantly decreased apo(a) secretion
when compared to 5 nM of lomitapide treatment. Next, we assessed secretion of the 17K7,8
apo(a) variant to determine if lomitapide’s ability to decrease apo(a) secretion was
dependent on the wLBS in apo(a). As demonstrated in Fig. 3.5 A (right), treatment of
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17K7,8 HepG2 cells with 5 nM, 10 nM, or 20 nM of lomitapide did not significantly affect
apo(a) secretion into conditioned medium when compared to control.
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Figure 3.5: Treating HepG2 cells with lomitapide affects apo(a) metabolism differently
dependent on the presence or absence of the weak lysine binding sites in KIV7 and KIV8.
Pulse-chase analysis of HepG2 cells stably expressing 17K apo(a) and HepG2 cells
transiently expressing 17K△7,8 apo(a) treated with 5nM, 10nM or 20nM of lomitapide
compared to control. Cells were pre-incubated for 4 hours in complete medium containing
0.4mM BSA-conjugated oleic acid and 0nM, 5nM, 10nM or 20nM of lomitapide. Cells
were then starved in Cys/Met free medium for one hour, pulse labelled with 35S-Cys/Met
for one hour, and subsequently chased for 0 minutes, 30 minutes, 60 minutes 120 minutes
and 360 minutes. For the chase period, cells were incubated in unlabelled complete medium
containing 0.4mM BSA-conjugated oleic acid and either 0nM, 5nM, 10nM or 20nM of
lomitapide; conditioned medium and lysate samples were collected from cells at the
indicated times of chase. Samples were then subjected to apo(a) pull-down
immunoprecipitation, and then analyzed by 6% SDS-PAGE and fluorography. The lower
band (450kDa) represents an immature hypo-glycosylated form of apo(a), while the
higher band (550kDa) represents a mature, fully glycosylated form of apo(a). (A) Media
samples of 17K apo(a) HepG2 cells treated with 0nM, 5nM, 10nM or 20nM of lomitapide.
(B) Lysate samples of 17K apo(a) HepG2 cells treated with 0nM, 5nM, 10nM or 20nM of
lomitapide. Densitometric band analysis was conducted using the ImageJ software,
normalized to the maximum observed density for 0nM lomitapide treatment, and plotted
as a function of time. The presented data corresponds to the means  SEM of 3 or 4
independent experiments. Significance compared to control is represented by asterisks
where *p<0.05, and **p<0.01. Significance compared to 5nM of lomitapide is represented
by daggers where †p<0.05, ††p<0.01, and †††p<0.001. The coloured lines representing the
different treatment concentrations are indicated on the figure.
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Cell lysates were also analyzed to determine if lomitapide could impact the intracellular
abundance of apo(a). The representative fluorograms (Fig. 3.5 B) of cell lysates across all
of the treatment groups demonstrate that apo(a) can be observed in both its immature form
(450kDa) from 0-360 minutes, and its mature form (550kDa) from 30-360 minutes,
similar to what was shown in Fig. 3.3. As demonstrated in Fig. 3.5 B (left; blue line), apo(a)
intracellular abundance in 17K HepG2 cells was not significantly affected by 5 nM of
lomitapide treatment compared to control. Although statistical significance was not
attained, there was an observable trend between 5 nM of lomitapide treatment and
increased apo(a) intracellular abundance when compared to control. Treatment of 17K
HepG2 cells with 10 nM of lomitapide resulted in significantly increased intracellular
abundance of apo(a) at the time zero and the 60-minute chase time versus control (Fig. 3.5
B; left, green line). Treatment with 10 nM of lomitapide was also able to significantly
increase the intracellular abundance of apo(a) in 17K HepG2 cells when compared to 5 nM
lomitapide treatment at time zero of the chase period (Fig. 3.5 B; left, green line).
Treatment of 17K HepG2 cells with 20 nM of lomitapide maximally increased the
intracellular abundance of apo(a). As demonstrated in Fig. 3.5 B (left; red line), treatment
of 17K HepG2 cells with 20 nM significantly increased the intracellular abundance of
apo(a) at the 0-minute, 30-minute, 60-minute and 120-minute chase times versus control.
Treating 17K HepG2 cells with 20 nM of lomitapide was also able to significantly increase
the intracellular abundance of apo(a) when compared to treatment with 5 nM of lomitapide
at time zero of the chase period (Fig. 3.5 B; left). The intracellular abundance of the 17K7,8
apo(a) variant was also analyzed in 17K7,8 HepG2 cells in response to lomitapide
treatment. Intriguingly, treatment of 17K7,8 HepG2 cells with 5 nM, 10 nM and 20 nM of
lomitapide did not significantly affect the intracellular abundance of 17K7,8 apo(a) when
compared to control (Fig. 3.5 B; right).
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3.6 Lomitapide treatment decreases apoB-100 secretion
and intracellular abundance in HepG2 cells
As demonstrated in Fig. 3.5, the ability of lomitapide to modulate apo(a) metabolism
appears to be dependent on the presence of the wLBS in KIV7,8. Because the wLBS in
KIV7,8 has been shown to be involved in noncovalent interactions with apoB-100, we
treated 17K HepG2 cells and 17K7,8 HepG2 cells with lomitapide and then analyzed apoB100 secretion and intracellular abundance to gain further insight into how lomitapide
regulates apo(a) metabolism. As demonstrated in Fig. 3.6 A (left), treatment of 17K HepG2
cells with 10 nM of lomitapide significantly reduced the secretion of apoB-100 at the 30minute, 60-minute, 120-minute and 360-minute chase points versus control. Similarly, as
shown in Fig. 3.7 A (right), treatment of 17K7,8 HepG2 cells with 10 nM lomitapide also
significantly reduced the secretion of apoB-100 at the 30-minute, 60-minute, 120-minute
and 360-minute chase times versus the no treatment control.
Cell lysates were analyzed to determine if the wLBS in KIV7,8 of apo(a) alters the
relationship between lomitapide treatment and apoB-100 intracellular abundance. As
demonstrated in Fig. 3.6 B (left), treatment of 17K HepG2 cells with 10 nM of lomitapide
significantly decreased the intracellular abundance of apo-B100 at the 0-minute and 30minute chase times versus the no treatment control. Similarly, treatment of the 17K7,8
HepG2 cells with 10 nM of lomitapide significantly decreased the intracellular abundance
of apoB-100 at the 0-minute, 30-minute, and 60-minute chase times versus the no treatment
control (Fig. 3.6 B; right). In summary, lomitapide treatment was able to decrease the
secretion and intracellular abundance of apoB-100 independent of the presence or absence
of a wLBS in apo(a).
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Figure 3.6: Lomitapide treatment decreases apoB-100 secretion and intracellular
abundance in HepG2 cells independent of apo(a) coexpression. Pulse-chase analysis of
HepG2 cells stably expressing 17K apo(a) and HepG2 cells transiently expressing 17K△7,8
apo(a) in the presence or absence of 10nM of lomitapide. Cells were pre-incubated for 4
hours in complete medium containing 0.4mM BSA-conjugated oleic acid in the presence
or absence of 10nM lomitapide. Cells were then starved in Cys/Met free medium for one
hour, pulse labelled with 35S-Cys/Met for one hour, and subsequently chased for 0 minutes,
30 minutes, 60 minutes 120 minutes and 360 minutes. Cells were chased in unlabelled
complete medium containing 0.4mM BSA-conjugated oleic acid in the presence or absence
of 10nM lomitapide. Conditioned medium and lysate samples were collected from cells
treated with either 0nM or 10nM of lomitapide at the indicated times of chase. Samples
were then subjected to apoB-100 immunoprecipitation, and then analyzed by 6% SDSPAGE and fluorography. (A) Media samples of 17K apo(a) HepG2 cells incubated in the
presence or absence of 10nM lomitapide. (B) Lysate samples of 17K apo(a) HepG2 cells
incubated in the presence or absence of 10nM lomitapide. Densitometric band analysis was
conducted using the ImageJ software, normalized to the maximum observed density for no
lomitapide treatment, and plotted as a function of time. The presented data correspond to
the mean  SEM of 3 or 4 independent experiments. Significance compared to control
(0nM lomitapide) is represented by asterisks where *p<0.05, and **p<0.01.
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Chapter 4

4

Discussion

Elevated levels of plasma Lp(a) have recently been recognized as the single most prevalent
inherited risk factor for CVD [21]. Importantly, it has been identified that approximately
20% of the global population have Lp(a) levels in excess of 50 mg/dL, which is a plasma
Lp(a) concentration that has been associated with a 2-fold increased risk of myocardial
infarction [21, 70] Although elevated Lp(a) levels are now recognized as a causal risk
factor for CAD, there are currently no clinically approved pharmacological therapies
available to specifically lower Lp(a) levels [20]. The absence of specific Lp(a)-lowering
therapies strongly reflects the limited understanding of Lp(a) biology, including how the
particle is assembled and secreted from liver hepatocytes.
It had generally been accepted that Lp(a) formation occurs exclusively extracellularly and
involved freely secreted apo(a) interacting covalently with circulating LDL. However, this
idea has recently been challenged by in vivo human kinetic studies, which have shown that
the production rate of the apoB-100 component of Lp(a) and the production rate of apo(a)
are quite similar [76]. Furthermore, this work has also demonstrated that the production
rate of apoB-100 in Lp(a) appears to be very different from the production rate of other
particles containing apoB-100, such as VLDL. Taken together, these studies suggest that
the secretion of apo(a) is closely coupled to the secretion of a unique pool of Lp(a)-specific
apoB-100, and that Lp(a) particle assembly may in part occur intracellularly.
Although an intracellular Lp(a) assembly dogma was initially challenged by the inability
to isolate covalently linked apo(a) and apoB-100 from cell lysates, a noncovalent
interaction between apo(a) and apoB-100 within the secretory pathway cannot be ruled out.
As mentioned, Lp(a) has been hypothesized to assemble in two-steps. The second step of
Lp(a) assembly is believed to involve the covalent interaction between apo(a) and the
apoB-100 component of an LDL-like particle. This step of Lp(a) assembly appears to occur
exclusively extracellularly, both because very few studies have isolated covalently linked
apo(a) and apoB-100 complexes from cell lysates [77], and because a unique oxidase
capacity of the extracellular environment seems to promote covalent Lp(a) assembly [85].
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The first step of Lp(a) assembly has been hypothesized to involve noncovalent interactions
between the wLBS in KIV7,8 of apo(a) with specific lysine residues in apoB-100, and likely
serves to properly orient the molecules for the subsequent formation of the covalent bond
[81]. Importantly, it is not yet known whether this noncovalent interaction between apo(a)
and apoB-100 occurs intracellularly. However, as mentioned, the in vivo human kinetic
studies have demonstrated that the production rates of apo(a) and Lp(a)-specific apoB-100
are quite similar, and thus it would seem plausible that step-one of Lp(a) formation occurs
intracellularly. Because production is the primary determinant of plasma Lp(a) levels [62],
further understanding the processes of Lp(a) assembly and secretion, such as whether
apo(a) and apoB-100 interact within liver hepatocytes, is critical information necessary to
aid in the development of specific Lp(a)-lowering pharmaceutical therapies.

4.1 Human sortilin polymorphisms increase apo(a)
secretion
GWA studies, rodent studies, and in vitro work have all implicated sortilin as a modulator
of LDL-C. Although it has been consistently demonstrated that sortilin overexpression and
knockdown are associated with altered levels of apoB-100 secretion or LDL clearance, the
direction of the relationship between sortilin expression and plasma cholesterol levels
remains controversial. For example, while one group has demonstrated that sortilin
knockout in mice is associated with decreased plasma cholesterol levels [155], another
group has shown that sortilin overexpression in HEK 293 cells induces increased
cholesterol uptake [156]. These disparities highlight the complex nature of the relationship
between sortilin and plasma cholesterol levels.
More recent genomic studies have also identified specific variants in the SORT1-encoding
1p13 locus as being causally associated with altered plasma Lp(a) levels [158]. In line with
this finding, previous unpublished work from our lab (Gemin, M.) has demonstrated that
sortilin overexpression is associated with increased apo(a) secretion from HepG2 cells,
while sortilin knockdown, and mutation of sortilin’s cytoplasmic targeting sequences, are
associated with decreased apo(a) secretion. Interestingly, co-IP work in our lab has also
shown that sortilin can bind directly to apoB-100, but cannot interact with apo(a), which
suggests that sortilin modulates apo(a) secretion indirectly, potentially through intracellular
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interactions with apoB-100. In order to further understand the role of sortilin in apo(a)
secretion, and to gain additional insight into Lp(a) assembly and secretion, we collaborated
with Dr. Robert Hegele at Robarts Research Institute and performed deep sequencing of
the SORT1 locus in 1740 patients with dramatically elevated Lp(a) levels. Importantly, we
identified 7 unique SORT1 polymorphisms within 9 individuals that had Lp(a) levels in the
top 5th percentile of the general population. It was later determined that the I124V, K205N,
K302E, F404Y, E444Q, and E447G amino acid substitution variants occurred specifically
within sortilin’s ten-bladed -propeller ligand binding domain. The V650M variant, which
is the only variant found outside of the -propeller domain, occurs within a highly
conserved 10CC module. The 10CC module is found adjacent to the transmembrane
domain, consists of 10 cysteine residues, and has also been shown to participate in ligand
binding [162]. Overall, these single amino acid substitutions result in conserved
replacements (where one amino acid is changed to another with similar properties; e.g.
I124V), loss of charge replacements (e.g. E444Q), and charge change replacements (where
a positive charge is changed for a negative charge or vice versa; e.g. K302E). In each case,
all of these substitutions could potentially alter the interaction between the sortilin receptor
and its ligand.
To gain insight into how these specific SORT1 polymorphisms contribute to elevated
plasma Lp(a) levels, we transiently transfected expression plasmids containing the 7
sortilin variants individually into HepG2 cells expressing a physiologically relevant 17kringle apo(a) isoform and then studied apo(a) secretion using pulse-chase analysis.
Overall, transfection of HepG2 cells with either wild-type sortilin or one of the 7 human
sortilin polymorphic variants increased apo(a) secretion relative to empty-vector control
(Fig. 3.1). These results are supported by work completed in mouse hepatocytes, which
demonstrated that sortilin overexpression promoted ligand localization towards the golgi
and secretory pathway [155]. These findings are also in line with previous work from our
lab, and potentially further implicate sortilin as an intracellular receptor that augments
apo(a) secretion. Importantly, the I124V, K205N, K302E, F404Y, E444Q, E447G and
V650M sortilin variants significantly increased apo(a) secretion compared to empty-vector
control (Fig. 3.1). Furthermore, the K302E, F404Y, and E444Q human sortilin

78

polymorphisms significantly increased apo(a) secretion versus wild-type sortilin control.
Therefore, the elevated plasma Lp(a) levels observed in individuals possessing these
sortilin variants may be attributable to increased apo(a) secretion. Because individuals that
possessed these amino acid substitutions had Lp(a) levels within the top 5th percentile of
the general population, it was hypothesized that each variant would increase apo(a)
secretion relative to wild-type control. Unexpectantly, transfection of HepG2 cells with the
I124V, K205N, E447G and V650M sortilin variants did not significantly impact apo(a)
secretion compared to wild-type control. One limitation to this study was that we did not
have access to the specific apo(a) isoform sizes expressed within the individuals that had
deep sequencing of their SORT1 locus performed. In our study, we utilized a 17K apo(a)
isoform, which has 8 repeated KIV2 domains. However, it is important to remember that
KIV2 ranges from 3 to over 30 identical tandem repeats in the human population [32].
Thus, due to high allelic heterogeneity, it is unlikely that those individuals identified as
having elevated Lp(a) levels and either the I124V, K205N, E447G or the V650M sortilin
variant, also possessed the 17K apo(a) isoform used in this study. Therefore, it could be
possible that different apo(a) isoform sizes impact sortilin’s interactions with apoB-100,
which thus affects sortilin’s ability to indirectly augment apo(a) secretion. This explanation
could account for why the I124V, K205N, E447G and V650M polymorphisms did not
increase the secretion of 17K apo(a) in our study. It is also important to recall that sortilin
can localize to the plasma membrane and function as an endocytic cell surface receptor.
For example, sortilin-mediated endocytosis of Progranulin is believed to play a key role in
the pathogenesis of fronto-temporal lobar degeneration [164]. In this study, we did not
analyze apo(a) internalization. Therefore, it could be possible that the elevated plasma
Lp(a) levels observed in individuals with the I124V, K205N, E447G or V650M sortilin
variants are attributable to decreased Lp(a) uptake.
Previous work from our lab has also demonstrated that sortilin increases the intracellular
abundance of apo(a). Work completed in this thesis confirms that finding, as a general
trend between sortilin overexpression and apo(a) intracellular abundance was observed
(Fig. 3.1). The I124V, K205N, K302E, F404Y, E444Q, and V650M amino acid
substitutions all significantly increased the intracellular abundance of apo(a) relative to
empty-vector control. Moreover, the K302E and F404Y variants, which significantly

79

increased apo(a) secretion relative to wild-type sortilin, also significantly increased apo(a)
intracellular abundance relative to wild-type control. This data further supports a role for
sortilin as a regulator of apo(a) secretion through decreasing apo(a) intracellular
degradation. Unexpectantly, the E447G variant was able to increase apo(a) secretion,
without increasing its intracellular abundance. Importantly, the glutamic acid to glycine
substitution results in a loss of charge replacement. It could be possible that this net loss of
negative charge within the -propeller domain of sortilin impacts the interaction between
the receptor and its ligand. This specific substitution at position 447 may augment sortilin’s
ability to bind to apoB-100 enough to increase apo(a) secretion through constitutive
secretory granules, but not enough to prevent dissociation of apoB-100 and apo(a) at the
lysosome. The inability of this variant to prevent apo(a) degradation might also help
explain why E447G overexpression was unable to increase apo(a) secretion to the level of
the K302E, F404Y, and E444Q variants. A similar unexpected finding was the observation
that the E444Q variant was able to significantly increase apo(a) secretion relative to wildtype sortilin but was unable to increase apo(a) intracellular abundance relative to wild-type
sortilin. Importantly, similar to the E447G substitution, the E444Q substitution results in a
loss of negative charge replacement. Therefore, it appears that these specific loss of
negative charge substitutions result in increased apo(a) secretion but are unable to prevent
intracellular apo(a) degradation. Based on this finding, it could be predicted that the
observed increase in apo(a) secretion by the loss of charge variants would not be
sustainable beyond 360 minutes due to decreased intracellular apo(a) bioavailability
secondary to increased intracellular degradation.
Apo(a) is first synthesized into the ER in an immature hypo-glycosylated form. As apo(a)
is translated into the ER, N-linked glycosylation is occurring within the KIV domains,
which appears to be crucial for proper protein folding [66]. Within the medial to trans golgi,
apo(a) reaches its mature form after O-linked glycans are added to the linker regions
between kringle domains [66]. Sortilin is first synthesized as a propeptide in order to
prevent premature ligand binding [139]. As the sortilin propeptide enters the TGN, furin
cleavage releases the prodomain, which enables the mature receptor to obtain full ligand
binding capacity. Therefore, the TGN is the subcellular location at which sortilin obtains

80

full ligand binding capacity, and the location where apo(a) receives O-linked glycosylation
and transitions to its 550 kDa mature form. Based on our hypothesis, sortilin is in some
way interacting with the mature form of apo(a) in the TGN, and this association acts to
both prevent apo(a) degradation, as well as to facilitate apo(a) secretion. Based on the idea
that sortilin is interacting with and preventing the degradation of apo(a), it might thus be
expected that the ratio of mature apo(a) to immature apo(a) would be increased in cells
transfected with wild-type sortilin, and cells transfected with the various sortilin variants
that augmented apo(a) intracellular abundance. Unexpectantly, analysis of differences in
apo(a) maturation between the various sortilin mutants and wild-type sortilin or emptyvector control revealed no significant differences in the ratio or rate of transition from the
immature hypo-glycosylated form to the mature fully glycosylated form (Fig. 3.1). In
retrospect, one specific limitation to this study was that the first two apo(a) chase times
were at 0 and 120 minutes. In comparison to empty-vector control, it could be possible that
wild-type sortilin and the sortilin variants increased the relative ratio of mature apo(a) to
immature apo(a) by associating with and preventing the intracellular degradation of mature
apo(a) between 0-minutes and 120-minutes of chase. However, because sortilin
overexpression was also associated with increased apo(a) secretion, the ratio of mature
apo(a) to immature apo(a) might have been reduced by the 120-minute chase time as a
result of augmented secretion of mature apo(a). Conversely, the lack of difference in apo(a)
maturation rates could be due to sortilin binding to and stabilizing the immature form of
apo(a). As mentioned, apo(a) glycosylation begins in the ER as N-linked glycans are added
to the newly translated protein. However, the addition of O-linked glycans, which accounts
for the bulk of the mass of apo(a) maturation, is a late golgi event [164]. Therefore, it is
likely that immature apo(a) is present within the late golgi, which as mentioned, is the
subcellular location where sortilin obtains its ligand binding capacity. Importantly, in vitro
studies have demonstrated that the immature hypo-glycosylated form of apo(a) is able to
associate with apoB-100 [164]. Therefore, it could be possible that immature apo(a)
associates with apoB-100 within the late golgi, at which point that complex could also
interact with sortilin. If sortilin is able to associate and prevent the degradation of immature
apo(a), and then remain complexed with mature apo(a), this might explain why differences
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in the ratio of mature apo(a) to immature apo(a) were not observed in cells transfected with
wild-type sortilin or a human sortilin variant.
In summary, we have demonstrated that overexpression of the I124V, K205N, K302E,
F404Y, E444Q, E447G and V650M human sortilin polymorphisms significantly increases
apo(a) secretion versus empty-vector control. Furthermore, with the exception of the
E447G variant, each sortilin polymorphism significantly increased the intracellular
abundance of apo(a) versus empty-vector control. These findings suggest that the elevated
Lp(a) levels observed in individuals with either the I124V, K205N, K302E, F404Y,
E444Q, E447G or V650M sortilin polymorphisms may in part be due to decreased
intracellular apo(a) degradation and increased apo(a) secretion. Previous work in our lab
has demonstrated that sortilin can physically associate with apoB-100, but cannot interact
with apo(a). Moreover, sortilin did not affect the secretion of apo(a) lacking the wLBS in
KIV7,8, which is believed to be important for mediating noncovalent interactions with
apoB-100. Although sortilin cannot physically associate with apo(a), this study provides
further evidence that sortilin and human sortilin polymorphic variants are able to regulate
apo(a) secretion. Therefore, it appears that apo(a) metabolism is modulated by sortilin
indirectly, potentially through intracellular noncovalent interactions with apoB-100.

4.2 Sortilin increases apoB-100 secretion only when
apo(a) is coexpressed
We have demonstrated in this thesis that a relationship exists between sortilin
overexpression and increased apo(a) secretion. As mentioned, it has previously been shown
in our lab that mutation of the wLBS in KIV7 and KIV8, thought to be important for the
initial non-covalent interactions with apoB-100, prevents sortilin from affecting apo(a)
secretion (Gemin, M., unpublished data). This finding, coupled with the fact that high
affinity binding between apoB-100 and sortilin has been documented [153 154], suggests
that a noncovalent intracellular interaction exists between apoB-100 and apo(a), and that
sortilin increases apo(a) secretion indirectly by increasing apoB-100 secretion. However,
this theory is challenged by a previous study in mice, which demonstrated that sortilin
overexpression decreased apoB-100 secretion through increasing apoB-100 lysosomal
degradation [134]. If sortilin directs apoB-100 towards the lysosome for degradation, and
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if apo(a) and apoB-100 noncovalently interact within the cell, it could be expected that
sortilin would decrease the secretion of apo(a) by facilitating its trafficking to the lysosome
indirectly through an interaction with apoB-100. Notwithstanding, it is important to
acknowledge that the aforementioned apoB-100 secretion studies were performed in mice,
which is an animal model that does not express apo(a). Therefore, we hypothesized that if
apo(a) and apoB-100 interact intracellularly, it could be possible that this association
affects the nature of the physical interaction between sortilin and apoB-100, and alters the
sortilin-mediated trafficking patterns of apoB-100.
To test this hypothesis, we performed pulse-chase analysis to study apoB-100 secretion in
response to sortilin overexpression from wild-type HepG2 cells (which do not express
apo(a)) and from HepG2 cells stably expressing a physiologically-relevant 17-kringle
apo(a) isoform. In line with findings from Musunuru’s group [134], sortilin overexpression
in our wild-type HepG2 cells resulted in both decreased apoB-100 secretion, and decreased
apoB-100 intracellular abundance (Fig. 3.2). This pattern of metabolism is characteristic
of increased intracellular degradation, and suggests that sortilin overexpression mediates
the trafficking of apoB-100 towards the lysosome in wild-type HepG2 cells. Interestingly,
the opposite trend was observed in the 17K apo(a) HepG2 cells. Sortilin overexpression in
17K apo(a) HepG2 cells increased both the secretion and intracellular abundance of apoB100 (Fig. 3.2). This pattern of metabolism is similar to what was observed for apo(a)
secretion, and suggests that sortilin is acting to increase the secretion of apoB-100 by
preventing its intracellular degradation in these cells.
These findings provide strong, albeit indirect, evidence of an intracellular interaction
between apo(a) and apoB-100. The only variable modulated between the studies analyzing
apoB-100 secretion in response to sortilin overexpression in the wild-type HepG2 cells,
and the studies analyzing apoB-100 secretion in response to sortilin overexpression in the
17K apo(a) HepG2 cells, was the coexpression of apo(a). Intriguingly, the presence of
intracellular apo(a) was sufficient to completely reverse the nature of the relationship
between sortilin overexpression and apoB-100 secretion. Although the exact mechanisms
have not been elucidated, it could be possible that the binding of apo(a) to apoB-100 within
the cell alters the physical interaction between apoB-100 and sortilin. By modifying how
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apoB-100 associates with sortilin, the presence of apo(a) may in turn alter the intracellular
trafficking patterns of apoB-100. This idea that apoB-100 metabolism can be altered
through its physical interaction with apo(a) is also supported through studies of Lp(a)
catabolism. The LDL-R is the main receptor responsible for clearance of plasma LDL.
Despite the numerous structural similarities between Lp(a) and LDL, only a small
proportion of plasma Lp(a) is cleared through the LDL-R under normal physiological
conditions [118]. This observation has led to the hypothesis that the association between
apo(a) and apoB-100 in Lp(a) physically disrupts the typical interactions between apoB100 and the LDL-R. The finding that sortilin overexpression mediates increased apoB-100
secretion and intracellular abundance also helps support our hypothesis that sortilin
increases apo(a) secretion indirectly through increasing apoB-100 secretion (Fig. 3.1).
Because sortilin cannot physically associate with apo(a) (Gemin, M., unpublished data),
and because apoB-100 and apo(a) display the same patterns of secretion and intracellular
abundance in 17K apo(a) cells, it seems likely that an intracellular interaction between
apo(a) and apoB-100 can account for the observed sortilin-mediated increases in apo(a)
secretion and intracellular abundance.
In summary, the nature of the relationship between sortilin and apoB-100 secretion remains
complex and controversial. While some groups have observed a direct relationship between
sortilin expression and apoB-100 secretion [155], others have observed an inverse
relationship [156]. For this reason, it has been postulated that the directionality of the
relationship between sortilin expression and apoB-100 secretion can be influenced by both
intracellular and extracellular metabolic conditions, as well as the specific experimental
model used. In this study, we demonstrate that the coexpression of apo(a), potentially
through intracellular interactions with apoB-100, influences the direction of the
relationship between sortilin overexpression and apoB-100 secretion. Therefore, it appears
that the presence of intracellular apo(a) is another factor which could help explain some of
the disparate findings in the field regarding sortilin and apoB-100 metabolism.
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4.3 PCSK9 increases the secretion and intracellular
abundance of both apo(a) and apoB-100
PCSK9 is unique from other members of the proprotein convertase family in that it
possesses no zymogen activation activities [103]. Although PCSK9 has no apparent
enzymatic activities, it has been shown to be an important transport and trafficking receptor
[103]. PCSK9 is best known for its role in LDL metabolism. Under normal circumstances,
the binding of LDL to the LDL-R triggers clathrin-dependent endocytosis [110]. As the
LDL/LDL-R complex moves from the endosome to the lysosome, the low pH environment
of the lysosome causes the dissociation of the LDL-R from LDL [110]. At this point, the
LDL-R can then be recycled back to the plasma membrane to facilitate further uptake of
LDL. Like LDL, PCSK9 can also bind to the LDL-R at the cell surface and trigger
endocytosis. However, it has been demonstrated that the binding of PCSK9 to the LDL-R
in the low pH environment of the lysosome prevents the dissociation and recycling of the
LDL-R to the cell surface [112]. As a consequence, the binding of PCSK9 to the LDL-R
impairs cholesterol clearance from the plasma by inducing increased lysosomal
degradation of the LDL-R [113]. Interestingly, a role for PCSK9 in the regulation of apoBcontaining lipoprotein assembly and secretion has also been recently demonstrated. Pulsechase studies conducted in LDL-R-/- mouse hepatocytes showed that PCSK9 expression
augments both the intracellular abundance and secretion of apoB-100 [114]. Therefore, it
appears that PCSK9 promotes increased plasma cholesterol levels by decreasing LDL
catabolism and by increasing apoB-containing lipoprotein anabolism.
Because of its ability to augment plasma cholesterol levels, PCSK9 has become a popular
LDL-lowering therapeutic target. The two most promising inhibitors of PCSK9,
evolocumab and alirocumab, have been demonstrated to effectively lower plasma LDL-C
levels by up to 60% [116]. Intriguingly, evolocumab and alirocumab have also been shown
to lower plasma Lp(a) levels by approximately 30% through a currently unknown
mechanism [117]. It has been postulated that the decreased plasma Lp(a) levels induced by
evolocumab and alirocumab treatment are due to increased Lp(a) catabolism through the
LDL-R, which is similar to how plasma LDL levels are believed to be lowered by this drug
class. However, this theory is challenged by work that has shown that the LDL-R does not
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play a significant role in the clearance of Lp(a) under normal physiological conditions
[118]. In further opposition, the statin class of drugs, which also augments levels of the
LDL-R at the cell surface, does not appear to be effective in lowering Lp(a) [14]. These
findings suggest that evolocumab and alirocumab lower plasma Lp(a) levels through a
mechanism independent of the LDL-R. In support of this idea, it has recently been shown
that treatment of human hepatocytes with PCSK9 results in a 3-fold decrease in apo(a)
secretion [122]. Importantly, this effect was reversed by alirocumab treatment [122].
However, this finding is seemingly contradicted by work from our lab, which has shown
an inability for PCSK9 to directly associate with apo(a) [160]. This finding, coupled with
work that has demonstrated a role for PCSK9 in augmenting apoB-100 secretion, led us to
postulate that the observed PCSK9-induced increases in apo(a) secretion are occurring
indirectly through intracellular noncovalent interactions with apoB-100.
In order to both gain further mechanistic understanding of Lp(a) assembly and secretion,
and identify a role for PCSK9 in Lp(a) metabolism, we treated 17K apo(a) HepG2 cells
and 17K7,8 apo(a) HepG2 cells (an apo(a) variant that lacks the wLBS in KIV7,8) with
PCSK9 and then analyzed apo(a) and apoB-100 secretion using pulse-chase studies. In
support of the findings from Villard’s group [122], work in this thesis has demonstrated
that PCSK9 treatment significantly increases the secretion of apo(a) from 17K apo(a)
HepG2 cells relative to control (Fig. 3.3). Furthermore, treatment of 17K apo(a) HepG2
cells with PCSK9 also significantly increased the intracellular abundance of apo(a),
suggesting a role for PCSK9 in preventing apo(a) degradation. This thesis also
demonstrates that PCSK9 treatment increases the secretion of apoB-100 versus control
(Fig. 3.4), which further supports the findings of Sun’s group [114]. Similar to what was
observed for apo(a), PCSK9 treatment of HepG2 cells also increased the intracellular
abundance of apoB-100, which again provides evidence of a role for PCSK9 in preventing
apoB-100 degradation.
Intriguingly, PCSK9 treatment did not affect apo(a) secretion or intracellular abundance
relative to control in HepG2 cells expressing the 17K7,8 apo(a) variant (Fig. 3.3). However,
PCSK9 treatment was still able to augment apoB-100 secretion and intracellular abundance
in these cells. As mentioned previously, the wLBS in KIV7,8 has been shown to facilitate
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noncovalent interactions with lysine residues in apoB-100. However, it remains unknown
whether or not this noncovalent interaction occurs intracellularly. Because mutation of the
wLBS in KIV7,8 in this study diminished the ability of PCSK9 to regulate apo(a)
metabolism, we believe that these findings provide evidence that an intracellular
noncovalent interaction exists between apo(a) and apoB-100. Previously, it has been
demonstrated that PCSK9 is able to tightly associate with apoB-100 [120]. This finding,
coupled with the fact that PCSK9 appeared to modulate apoB-100 secretion in a manner
independent of the apo(a) variant expressed, suggests that PCSK9 regulates apoB-100
secretion through direct physical interactions. On the other hand, PCSK9 was only able to
regulate the secretion and intracellular abundance of apo(a) that possessed the wLBS in
KIV7,8. Therefore, it seems likely that apo(a), through its wLBS, noncovalently interacts
with apoB-100 within the cell, and is indirectly being trafficked by PCSK9 due to its
association with apoB-100. In this sense, apo(a) secretion and intracellular abundance
appears to be increased by PCSK9 through a “piggyback” effect with apoB-100. In further
support of this idea that an intracellular interaction is occurring between apo(a) and apoB100, we observed that apoB-100 secretion was augmented to a greater extent in the 17K
apo(a) HepG2 cells than the 17K7,8 apo(a) HepG2 cells (Fig. 3.4). If apo(a) is interacting
with apoB-100 within the cell in such a way that the physical interaction between apoB100 and PCSK9 is modified, this could potentially increase the secretion of apoB-100
mediated through PCSK9 treatment.
It is important to note that both sortilin overexpression and PCSK9 treatment increased the
secretion and intracellular abundance of apoB-100 and apo(a) in a similar manner, which
might suggest that some redundancy exists between the two receptor pathways. However,
it has also been demonstrated by Gustafsen’s group that sortilin is able to associate with
PCSK9 and act as a trafficking receptor to augment its secretion [165]. As might be
expected, co-localization studies showed extensive interactions between sortilin and
PCSK9 in the TGN, which is the subcellular location where sortilin gains its ligand binding
capacity [152]. Based on the findings from the aforementioned study, it appears that sortilin
acts as a chaperone protein that regulates PCSK9 movement through the secretory pathway.
As previously mentioned, co-IP studies have demonstrated that both PCSK9 [114] and
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sortilin (Gemin, M., unpublished data) are able to directly associate with apoB-100.
Therefore, it could be possible that a sortilin/PCSK9/apoB-100/apo(a) complex forms in
the TGN and moves through the secretory pathway during Lp(a) biosynthesis. Because
PCSK9 has been shown to facilitate pH-dependent interactions with its ligands, like the
LDL-R, its presence could be important for the appropriate loading and unloading of the
complex within specific subcellular locations. On the other hand, because of its ability to
bind specific adaptor proteins and facilitate a role as a transport protein, sortilin’s presence
is likely essential for properly transporting the complex through the secretory pathway. It
would be interesting to study the secretion of apo(a) and apoB-100 in response to PCSK9
treatment from sortilin knockout cells. If sortilin is in fact responsible for properly shuttling
the sortilin/PCSK9/apo(a)/apoB-100 complex through the secretory pathway, it might be
expected that PCSK9 treatment in this cell line would not be able to mediate the increased
secretion of apo(a) and apoB-100 observed in this study.
In summary, we provide further evidence in this thesis to support a role for PCSK9 in
augmenting apo(a) and apoB-100 secretion. Importantly, it appears that PCSK9 is able to
increase the secretion of apo(a) indirectly through increasing the secretion of apoB-100.
Our work demonstrated that PCSK9 could only modulate the metabolism of apo(a)
isoforms possessing the wLBS in KIV7,8, but could modulate the secretion of apoB-100
independently of which apo(a) variant was expressed. Because the PCSK9-mediated
increases in apo(a) secretion appear to be dependent on the wLBS in KIV7,8, this work
further supports the existence of an intracellular interaction between apo(a) and apoB-100
in Lp(a) biosynthesis.

4.4 MTP inhibition decreases the secretion of both
apo(a) and apoB-100
MTP is an ER resident protein that is responsible for regulating the assembly of all apoBcontaining lipoproteins. Specific mutations within the M subunit lipid transfer domain of
MTP are phenotypically associated with abetalipoproteinemia, which is a disease
characterized by the complete absence of circulating apoB-containing lipoproteins [94]. It
has been hypothesized that the binding of MTP to apoB in the ER serves two functions
[129]. Firstly, it is thought that the binding of MTP to apoB serves to protect apoB from
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degradation. Importantly, when newly synthesized apoB becomes dislocated from the ER
membrane, it subsequently undergoes proteosomal degradation [130]. Therefore, by
binding to apoB and preventing its dislocation from the ER membrane, it is thought that
MTP protects newly synthesized apoB from degradation. Secondly, the lipid transfer
activity of MTP is thought to render apoB secretion competent [129].

The exact

mechanism behind how MTP transfers lipids to apoB, as well as where these lipids
originate from, is still not well understood [129]. Regardless of the mechanism, MTPmediated lipidation within the ER appears to be crucial in facilitating the secretion of apoB.
Similar to PCSK9, MTP’s ability to regulate the secretion of apoB-containing lipoproteins
has made it an attractive LDL-cholesterol lowering therapeutic target. Lomitapide is one
such MTP inhibitor that has proven to be effective in lowering plasma LDL by up to 40%
[93]. However, because MTP plays such a large role in apoB-containing lipoprotein
assembly and secretion, lomitapide treatment is often associated with increased hepatic fat
retention and plasma liver transaminase levels, and is thus restricted to use in high-risk
homozygous FH patients where other therapies have proven ineffective [93]. Intriguingly,
lomitapide treatment has also been shown to lower plasma Lp(a) levels by up to 13%
through a yet unknown mechanism [93].
As mentioned previously, it has been postulated by some groups that apo(a) is freely
secreted from liver hepatocytes and later associates with membrane-bound or circulating
LDL for form the Lp(a) particle [74, 166]. Based on this idea, the lomitapide-mediated
lowering of plasma Lp(a) would be due to decreased secretion of the apoB-containing
VLDL particle, which is the precursor to LDL. By lowering the secretion of VLDL, less
LDL would be available in the plasma for apo(a) to associate with, and thus fewer Lp(a)
particles would be assembled. However, the extracellular assembly model for Lp(a) has
been challenged by more recent kinetic studies, which have shown that the secretion rates
of apo(a) and apoB-100 are quite similar, and that there appears to be a unique apoB-100
pool destined specifically for Lp(a) assembly [76]. Based on these findings, it has been
postulated that instead of free apo(a) interacting with circulating LDL, an LDL-like particle
is synthesized de novo in liver hepatocytes and secreted together with apo(a). Although
these kinetic studies have shown that the apo(a) and apoB-100 components of Lp(a) are
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secreted at similar rates, whether or not these two proteins interact intracellularly has not
been directly observed. By studying the secretion of both apo(a) and apoB-100 in response
to lomitapide treatment in vitro, we hoped to gain insight into Lp(a) assembly and the
mechanism behind how lomitapide treatment reduces plasma Lp(a) levels.
In order to both gain further mechanistic understandings of Lp(a) assembly, and discern
how lomitapide treatment results in decreased plasma Lp(a) levels, we treated 17K apo(a)
HepG2 cells and 17K7,8 apo(a) HepG2 cells (an apo(a) variant that lacks the wLBS in
KIV7,8) with lomitapide and then analyzed apo(a) and apoB-100 secretion using pulsechase studies. Work in this thesis demonstrates that lomitapide treatment significantly
decreases the secretion and intracellular abundance of apoB-100 in HepG2 cells (Fig. 3.6).
These findings are in line with the work of Jamil’s group, who also showed that lomitapide
treatment significantly reduced apoB-100 secretion after a 30-minute lag interval [167].
Combined, this work supports a role for lomitapide in lowering plasma LDL through
decreasing the secretion of apoB-containing lipoproteins. Importantly, our work also
demonstrates that lomitapide treatment decreases apoB-100 secretion and intracellular
abundance independent of the apo(a) species expressed (Fig. 3.6).
Interestingly, we also show here that lomitapide significantly decreases the secretion of
17K apo(a) from HepG2 cells (Fig. 3.5). Based on the hypothesis that freely secreted apo(a)
interacts with circulating LDL to form Lp(a), it would not be expected that lomitapide
treatment would impact apo(a) secretion. We postulated that apo(a) secretion was
decreased by lomitapide treatment indirectly through intracellular interactions with apoB100 and decreased apoB-100 secretion. However, we could not neglect the possibility that
MTP physically associates with apo(a) in the ER and plays a more direct role in apo(a)
metabolism. To help decipher the mechanisms involved in lomitapide-mediated regulation
of apo(a) secretion, we used HepG2 cells expressing 17K7,8 apo(a), which again lacks the
wLBS in KIV7,8 thought to be involved in noncovalent interactions with apoB-100.
Importantly, lomitapide treatment was unable to affect the secretion or intracellular
abundance of the apo(a) variant lacking the wLBS in KIV7,8 (Fig. 3.5). Therefore, similar
to how sortilin and PCSK9 modulate apo(a) metabolism, it appears that lomitapide
decreases apo(a) secretion indirectly. By inhibiting the lipidation of apoB-100, which
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subsequently increases its proteosomal degradation, lomitapide likely reduces the amount
of apoB-100 available to associate with apo(a). As the amount of apoB-100 available to
associate with apo(a) decreases, the movement of apo(a) through the secretory pathway is
presumably impaired. As mentioned previously, co-IP studies have demonstrated the both
sortilin (Gemin, M., unpublished data) and PCSK9 [114] can physically interact with apoB100, but cannot associate with apo(a). Therefore, apo(a) secretion is likely unable to benefit
from the indirect increases in secretion mediated through the effects of PCSK9 and sortilin,
and instead partially accumulates somewhere upstream in the secretory pathway. This
theory is supported by our finding that lomitapide treatment significantly decreased the
intracellular abundance of apoB-100 (Fig. 3.6), but significantly increased the intracellular
abundance of 17K apo(a) (Fig. 3.5).
In summary, this work provides evidence to support a role for MTP in Lp(a) metabolism
through regulating the secretion of apoB-100. Furthermore, because lomitapide was able
to decrease the secretion of 17K apo(a), but had no effect on 17K7,8 apo(a) secretion, these
findings also provide evidence of an intracellular interaction between apo(a) and apoB100. The production of apo(a) is not thought to involve interactions with MTP, as apo(a)
does not undergo lipidation [168]. Therefore, it appears that by decreasing the intracellular
abundance of apoB-100 and consequentially reducing the intracellular interactions
between apo(a) and apoB-100, lomitapide treatment indirectly impedes apo(a) secretion. If
Lp(a) assembly did not involve an intracellular interaction between apo(a) and apoB-100,
it would seem unlikely that lomitapide-mediated modulation of apoB-100 secretion would
have any impact on apo(a) secretion. Taken together, work in this thesis also provides a
possible explanation as to how lomitapide treatment reduces plasma Lp(a) levels. Rather
than reducing the amount of circulating LDL available for free apo(a) to associate with,
our work suggests that lomitapide treatment directly inhibits the secretion of the Lp(a)
particle, which appears to assemble, at least partially, in liver hepatocytes.
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Figure 4.1: A model of the role of sortilin, PCSK9 and MTP on apoB-100 containing
lipoprotein secretion. Under normal conditions, a delicate balance between hepatic
secretion and intracellular degradation of apo(a), Lp(a), and other apoB-100-containing
lipoproteins is achieved (A, B, C). In the presence of sortilin and absence of apo(a), apoBcontaining lipoprotein degradation is increased (D). However, through a yet unknown
mechanism, the presence of sortilin results in decreased degradation and increased
secretion of apoB-containing lipoproteins that are interacting with apo(a) (E). Because
sortilin does not obtain full ligand binding capacity until reaching the late golgi, the
interactions between sortilin and apoB-containing lipoproteins likely occurs within the cis
or trans golgi compartments (green arrow). PCSK9 has been shown to directly interact with
apoB-100, protecting it from lysosomal degradation, and facilitating its secretion (F).
Despite evidence demonstrating an inability for PCSK9 to directly interact with apo(a),
treatment of HepG2 cells with PCSK9 results in augmented secretion of apo(a) (G). It
would seem plausible that this PCSK9-mediated increase in apo(a) secretion occurs as a
result of non-covalent intracellular interactions between apo(a) and apoB-100. Within the
ER (blue arrow), improperly lipidated lipoproteins are targeted for proteasomal
degradation (H, I). MTP localizes to the ER membrane where it prevents apoB-100
membrane dislocation and participates in primordial lipoprotein lipid loading and
assembly. By preventing the dislocation of apoB-100 from the ER membrane, MTP
protects apoB-100 from degradation, which subsequently results in increased apoBcontaining lipoprotein secretion (J). MTP also appears to have a role in facilitating apo(a)containing lipoprotein secretion (K), as inhibition of MTP with lomitapide results in
decreased apo(a) secretion. However, this effect of MTP inhibition on apo(a) secretion was
attenuated in apo(a) variants lacking the wLBS in KIV7-8. Therefore, it seems plausible that
apo(a) and apoB-100 interact intracellularly, and MTP increases apo(a) secretion indirectly
through augmenting the bioavailability and secretion of apoB-100.

93

4.5 Study limitations and future directions
To determine whether the observed effects of PCSK9 and lomitapide treatment on 17K
apo(a) secretion were due to a noncovalent intracellular interaction with apoB-100, an 17K
apo(a) variant lacking the wLBS in KIV7-8 (17K7,8 apo(a)) was utilized. In our study, we
measured wild-type 17K apo(a) secretion in response to lomitapide and PCSK9 treatment
from HepG2 cells stably expressing 17K apo(a). However, due to time constraints, one
limitation to this study was that 17K7,8 apo(a) secretion was measured from HepG2 cells
transiently expressing 17K7,8 apo(a). Future experiments conducted to examine the effects
of lomitapide and PCSK9 treatment on wild-type 17K apo(a) secretion and 17K7,8 apo(a)
secretion should utilize either HepG2 cells stably expressing both wild-type 17K apo(a) or
17K7,8 apo(a), or HepG2 cells transiently expressing both wild-type 17K apo(a) or 17K7,8
apo(a).
Finally, in this study we measured apo(a) secretion from HepG2 cells in response to either
wild-type sortilin, Sort-I124V, Sort-K205N, Sort-K302E, Sort-F404Y, Sort-E444Q, SortE447G, or Sort-V650M overexpression relative to empty-vector control. Although
Western Blot analysis of cellular lysates demonstrated comparable expression levels of
wild-type sortilin with the Sort-I124V, Sort-K205N, Sort-K302E, Sort-F404Y, SortE444Q, and Sort-E447G polymorphic variants, it did appear that the Sort-V650M variant
was expressed at slightly higher levels. In future studies, sortilin overexpression should be
normalized to β-actin expression. Subsequently, apo(a) secretion levels could then be
adjusted relative to the measured amount of sortilin overexpression.

4.6 Summary and Conclusions
Elevated levels of plasma lipoprotein(a) (Lp(a)) are the most prevalent inherited risk factor
for CVD, but development of specific Lp(a) lowering therapeutics has been hindered by a
lack of fundamental understanding of the lipoprotein’s biology. Lp(a) is believed to be
synthesized in two steps. The first step involves noncovalent associations between the
wLBS in KIV7,8 and lysine residues in apoB-100, and likely serves to properly orient the
apolipoproteins for step two. Step two of assembly involves a stronger covalent linkage
between a free cysteine in KIV9 of apo(a) with a free cysteine in the C-terminus of apoB-
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100. Because very few apo(a)/apoB-100 covalent complexes have ever been isolated from
cell lysates, it is generally accepted that step two occurs extracellularly. However, the
location of the step one noncovalent association remains enigmatic. To determine if a
noncovalent intracellular interaction exists between apo(a) and apoB-100 in Lp(a)
assembly and secretion, we modulated known cellular regulators of apoB-100 metabolism,
and then analyzed the secretion of both apo(a) and apoB-100. In this thesis, we have shown
that the presence of intracellular apo(a) can modulate the secretion patterns of apoB-100 in
response to sortilin overexpression. Furthermore, we have shown that the PCSK9 and
MTP-mediated regulation of apo(a) secretion is dependent on the wLBS in KIV7,8, which
is believed to be important in facilitating noncovalent interactions with apoB-100. Taken
together, work in this thesis suggests a role for sortilin, MTP, and PCSK9 in apo(a)
secretion, likely through modulating the bioavailability of apoB-100. Furthermore, our
work provides indirect evidence of a noncovalent intracellular interaction between apo(a)
and apoB-100 in Lp(a) assembly.
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